Cyclo Therapeutics (CYTH) S-1 29 Sep 20 2020 Q2 IPO registration Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2020
Document Information [Line Items]
Entity Registrant Name	Cyclo Therapeutics, Inc.
Entity Central Index Key	0000922247
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Document Type	S-1
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Amendment Flag	false

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
CURRENT ASSETS
Cash and cash equivalents	$ 1,008,355	$ 2,783,719
Accounts receivable	161,233	143,429
Inventory, net	216,609	242,630
Current portion of mortgage note receivable	39,061	39,061
Prepaid insurance and services	71,151	137,069
Prepaid clinical expenses	591,676	612,161
Total current assets	2,088,085	3,958,069
FURNITURE AND EQUIPMENT, NET	60,437	13,546
RIGHT-TO-USE LEASE ASSET, NET	42,515	51,017
MORTGAGE NOTE RECEIVABLE, LESS CURRENT PORTION	71,264	90,596
TOTAL ASSETS	2,262,301	4,113,228
CURRENT LIABILITIES
Current portion of lease liability	16,968	16,385
Current portion of long-term debt	60,879
Accounts payable and accrued expenses	3,979,395	3,124,735
Total current liabilities	4,057,242	3,141,120
LONG-TERM LIABILITIES
Long-term lease liability, less current portion	27,453	36,126
Long-term debt, less current portion	97,645
Total long-term liabilities	125,098	36,126
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock, par value $.0001 per share, 500,000,000 shares authorized, 141,671,462 and 121,564,990 shares issued and outstanding, at June 30, 2020 and December 31, 2019	14,155	12,155
Preferred stock, par value $.0001 per share, 5,000,000 shares authorized
Additional paid-in capital	28,012,423	26,044,060
Accumulated deficit	(29,946,617)	(25,120,233)
Total stockholders' equity (deficit)	(1,920,039)	935,982
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 2,262,301	$ 4,113,228

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018	May 23, 2018	May 22, 2018	Dec. 31, 2004
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	500,000,000	500,000,000	500,000,000	500,000,000	100,000,000
Common stock, shares issued (in shares)	141,671,462	121,564,990	90,759,324
Common stock, shares outstanding (in shares)	141,671,462	121,564,990	90,759,324
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000	5,000,000			5,000,000

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
REVENUES
Product sales	$ 209,594	$ 273,095	$ 535,328	$ 493,921
EXPENSES
Personnel	433,628	311,077	903,333	721,076
Cost of products sold (exclusive of direct and indirect overhead and handling costs)	12,947	16,309	39,380	36,859
Research and development	1,713,435	786,811	3,773,041	2,129,574
Repairs and maintenance	1,311	1,299	3,113	2,983
Professional fees	143,427	246,276	362,963	461,251
Office and other	79,823	247,495	258,185	350,137
Board of Directors fees and costs	21,367	31,611	28,716	64,696
Depreciation	3,118	1,485	6,236	2,969
Freight and shipping	1,169	1,016	3,032	2,450
Bad debt expense	1,272		1,272
Total operating expenses	2,411,497	1,643,379	5,379,271	3,771,995
LOSS FROM OPERATIONS	(2,201,903)	(1,370,284)	(4,843,943)	(3,278,074)
OTHER INCOME
Investment and other income	9,511	2,273	17,559	5,897
LOSS BEFORE INCOME TAXES	(2,192,392)	(1,368,011)	(4,826,384)	(3,272,177)
PROVISION FOR INCOME TAXES
NET LOSS	$ (2,192,392)	$ (1,368,011)	$ (4,826,384)	$ (3,272,177)
BASIC AND FULLY DILUTED NET LOSS PER COMMON SHARE (in dollars per share)	$ (0.02)	$ (0.01)	$ (0.04)	$ (0.03)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING (in shares)	136,676,101	101,013,435	129,120,546	95,886,380

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Receivables from Stockholder [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017	72,999,361
Balance at Dec. 31, 2017	$ 7,299	$ 14,470,984		$ (13,332,667)	$ 1,145,618
Net loss				(4,255,033)	(4,255,033)
Sale of common stock, net of issuance fees (in shares)	3,519,963
Sale of common stock, net of issuance fees	$ 352	2,271,649	(130,062)		2,141,939
Balance (in shares) at Dec. 31, 2018	90,759,324
Balance at Dec. 31, 2018	$ 9,075	18,701,211	(130,062)	(17,587,700)	992,524
Net loss				(1,904,166)	(1,904,166)
Collection of subscription receivable			130,062		130,062
Balance (in shares) at Mar. 31, 2019	90,759,324
Balance at Mar. 31, 2019	$ 9,075	18,701,211		(19,491,866)	(781,580)
Balance (in shares) at Dec. 31, 2018	90,759,324
Balance at Dec. 31, 2018	$ 9,075	18,701,211	(130,062)	(17,587,700)	992,524
Net loss					(3,272,177)
Balance (in shares) at Jun. 30, 2019	120,529,324
Balance at Jun. 30, 2019	$ 12,052	25,687,834		(20,859,877)	4,840,009
Balance (in shares) at Dec. 31, 2018	90,759,324
Balance at Dec. 31, 2018	$ 9,075	18,701,211	(130,062)	(17,587,700)	992,524
Net loss				(7,532,533)	(7,532,533)
Sale of common stock, net of issuance fees (in shares)	29,770,000
Sale of common stock, net of issuance fees	$ 2,977	6,986,623			6,989,600
Collection of subscription receivable			130,062		130,062
Balance (in shares) at Dec. 31, 2019	121,564,990
Balance at Dec. 31, 2019	$ 12,155	26,044,060		(25,120,233)	935,982
Balance (in shares) at Mar. 31, 2019	90,759,324
Balance at Mar. 31, 2019	$ 9,075	18,701,211		(19,491,866)	(781,580)
Net loss				(1,368,011)	(1,368,011)
Sale of common stock, net of issuance fees (in shares)	29,770,000
Sale of common stock, net of issuance fees	$ 2,977	6,986,623			6,989,600
Balance (in shares) at Jun. 30, 2019	120,529,324
Balance at Jun. 30, 2019	$ 12,052	25,687,834		(20,859,877)	4,840,009
Balance (in shares) at Dec. 31, 2019	121,564,990
Balance at Dec. 31, 2019	$ 12,155	26,044,060		(25,120,233)	935,982
Net loss				(2,633,992)	(2,633,992)
Balance (in shares) at Mar. 31, 2020	121,564,990
Balance at Mar. 31, 2020	$ 12,155	26,044,060		(27,754,225)	(1,698,010)
Balance (in shares) at Dec. 31, 2019	121,564,990
Balance at Dec. 31, 2019	$ 12,155	26,044,060		(25,120,233)	935,982
Net loss					(4,826,384)
Balance (in shares) at Jun. 30, 2020	141,564,990
Balance at Jun. 30, 2020	$ 14,155	28,012,423		(29,946,617)	(1,920,039)
Balance (in shares) at Mar. 31, 2020	121,564,990
Balance at Mar. 31, 2020	$ 12,155	26,044,060		(27,754,225)	(1,698,010)
Net loss				(2,192,392)	(2,192,392)
Sale of common stock, net of issuance fees (in shares)	20,000,000
Sale of common stock, net of issuance fees	$ 2,000	1,968,363			1,970,363
Balance (in shares) at Jun. 30, 2020	141,564,990
Balance at Jun. 30, 2020	$ 14,155	$ 28,012,423		$ (29,946,617)	$ (1,920,039)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (4,826,384)	$ (3,272,177)	$ (7,532,533)	$ (4,255,033)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	6,236	2,969	5,681	10,124
Accrued stock compensation to employees	4,810	13,100	19,340	19,400
Accrued stock compensation to nonemployees	9,250	54,830	61,030	64,020
Increase or decrease in:
Accounts receivable	(17,804)	(74,066)	(63,385)	(23,184)
Inventory	26,021	18,947	160,636	42,540
Prepaid clinical expenses	20,485	(178,200)	(612,161)
Prepaid insurance and services	65,918	(10,304)	(118,884)	42,661
Other	412	864	2,162
Accounts payable and accrued expenses	840,600	697,370	1,119,033	898,882
Total adjustments	955,928	525,510	943,046	1,066,593
NET CASH USED IN OPERATING ACTIVITIES	(3,870,456)	(2,746,667)	(6,589,487)	(3,188,440)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of furniture and equipment	(53,127)	(1,324)	(1,324)	(2,959)
Proceeds from mortgage note receivable	19,332	18,530	37,456	35,899
NET CASH PROVIDED BY INVESTING ACTIVITIES	(33,795)	17,206	36,132	32,940
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from PPP loan	158,524
Collection of stock subscription receivable		130,062	130,062
Proceeds from sale of common stock, preferred stock and warrants, net of issuance costs	1,970,363	6,989,600	6,989,600	4,101,939
NET CASH PROVIDED BY FINANCING ACTIVITIES	2,128,887	7,119,662	7,119,662	4,101,939
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(1,775,364)	4,390,201
CASH AND CASH EQUIVALENTS, beginning of period	2,783,719	2,217,412	2,217,412
CASH AND CASH EQUIVALENTS, end of period	1,008,355	6,607,613	2,783,719	2,217,412
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest
Cash paid for income taxes
NONCASH INVESTING AND FINANCING ACTIVITIES
Capitalization of right-to-use asset and lease liability		$ 60,383	$ 68,022

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash and cash equivalents	$ 2,783,719	$ 2,217,412
Accounts receivable	143,429	80,044
Inventory, net	242,630	416,531
Current portion of mortgage note receivable	39,061	37,439
Prepaid insurance and services	137,069	18,185
Prepaid clinical expenses	612,161
Total current assets	3,958,069	2,769,611
FURNITURE AND EQUIPMENT, NET	13,546	18,571
RIGHT-TO-USE LEASE ASSET, NET	51,017
MORTGAGE NOTE RECEIVABLE, LESS CURRENT PORTION	90,596	129,674
TOTAL ASSETS	4,113,228	2,917,856
CURRENT LIABILITIES
Current portion of lease liability	16,385
Accounts payable and accrued expenses	3,124,735	1,925,332
Total current liabilities	3,141,120	1,925,332
Long-term lease liability, less current portion	36,126
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock, par value $.0001 per share, 500,000,000 shares authorized, 141,671,462 and 121,564,990 shares issued and outstanding, at June 30, 2020 and December 31, 2019	12,155	9,075
Preferred stock, par value $.0001 per share, 5,000,000 shares authorized
Additional paid-in capital	26,044,060	18,701,211
Stock subscription receivable		(130,062)
Accumulated deficit	(25,120,233)	(17,587,700)
Total stockholders' equity (deficit)	935,982	992,524
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 4,113,228	$ 2,917,856

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018	May 23, 2018	May 22, 2018	Dec. 31, 2004
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	500,000,000	500,000,000	500,000,000	500,000,000	100,000,000
Common stock, shares issued (in shares)	141,671,462	121,564,990	90,759,324
Common stock, shares outstanding (in shares)	141,671,462	121,564,990	90,759,324
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000	5,000,000			5,000,000
Preferred stock, shares outstanding (in shares)		0	0

Consolidated Statements of Op_2

Consolidated Statements of Operations - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
REVENUES
Product sales	$ 209,594		$ 273,095		$ 535,328	$ 493,921	$ 1,007,198	$ 1,011,477
EXPENSES
Personnel	433,628		311,077		903,333	721,076	1,906,438	1,171,941
Cost of products sold (exclusive of direct and indirect overhead and handling costs)	12,947		16,309		39,380	36,859	75,493	105,026
Research and development	1,713,435		786,811		3,773,041	2,129,574	4,869,160	2,711,275
Repairs and maintenance	1,311		1,299		3,113	2,983	8,295	3,821
Professional fees	143,427		246,276		362,963	461,251	571,937	808,770
Office and other	79,823		247,495		258,185	350,137	845,624	354,102
Board of Directors fees and costs	21,367		31,611		28,716	64,696	109,473	95,431
Depreciation	3,118		1,485		6,236	2,969	5,681	10,124
Freight and shipping	1,169		1,016		3,032	2,450	5,885	5,643
Inventory valuation allowance							13,265	12,150
Total operating expenses	2,411,497		1,643,379		5,379,271	3,771,995	8,551,758	5,278,283
LOSS FROM OPERATIONS	(2,201,903)		(1,370,284)		(4,843,943)	(3,278,074)	(7,544,560)	(4,266,806)
OTHER INCOME
Investment and other income	9,511		2,273		17,559	5,897	12,027	11,773
LOSS BEFORE INCOME TAXES	(2,192,392)		(1,368,011)		(4,826,384)	(3,272,177)	(7,532,533)	(4,255,033)
PROVISION FOR INCOME TAXES							0	0
NET LOSS	$ (2,192,392)	$ (2,633,992)	$ (1,368,011)	$ (1,904,166)	$ (4,826,384)	$ (3,272,177)	$ (7,532,533)	$ (4,255,033)
BASIC AND FULLY DILUTED NET LOSS PER COMMON SHARE (in dollars per share)	$ (0.02)		$ (0.01)		$ (0.04)	$ (0.03)	$ (0.07)	$ (0.05)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING (in shares)	136,676,101		101,013,435		129,120,546	95,886,380	108,191,753	81,756,839

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Receivables from Stockholder [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017	72,999,361	15,500
Balance at Dec. 31, 2017	$ 7,299	$ 2	$ 14,470,984		$ (13,332,667)	$ 1,145,618
Sale of preferred stock units, net of issuance fees (in shares)		20,100				0
Sale of preferred stock units, net of issuance fees		$ 2	1,959,998			$ 1,960,000
Conversion of preferred stock units to common stock (in shares)	14,240,000	(35,600)
Conversion of preferred stock units to common stock	$ 1,424	$ (4)	(1,420)
Sale of common stock, net of issuance fees (in shares)	3,519,963
Sale of common stock, net of issuance fees	$ 352		2,271,649	(130,062)		2,141,939
Net loss					(4,255,033)	$ (4,255,033)
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture (in shares)		20,100				0
Stock-based compensation		$ 2	1,959,998			$ 1,960,000
Balance (in shares) at Dec. 31, 2018	90,759,324
Balance at Dec. 31, 2018	$ 9,075		18,701,211	(130,062)	(17,587,700)	992,524
Net loss					(1,904,166)	(1,904,166)
Collection of subscription receivable				130,062		130,062
Balance (in shares) at Mar. 31, 2019	90,759,324
Balance at Mar. 31, 2019	$ 9,075		18,701,211		(19,491,866)	(781,580)
Balance (in shares) at Dec. 31, 2018	90,759,324
Balance at Dec. 31, 2018	$ 9,075		18,701,211	(130,062)	(17,587,700)	992,524
Net loss						(3,272,177)
Balance (in shares) at Jun. 30, 2019	120,529,324
Balance at Jun. 30, 2019	$ 12,052		25,687,834		(20,859,877)	4,840,009
Balance (in shares) at Dec. 31, 2018	90,759,324
Balance at Dec. 31, 2018	$ 9,075		18,701,211	(130,062)	(17,587,700)	992,524
Sale of preferred stock units, net of issuance fees (in shares)	1,035,666
Sale of preferred stock units, net of issuance fees	$ 103		356,226			356,329
Sale of common stock, net of issuance fees (in shares)	29,770,000
Sale of common stock, net of issuance fees	$ 2,977		6,986,623			6,989,600
Net loss					(7,532,533)	(7,532,533)
Collection of subscription receivable				130,062		130,062
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture (in shares)	1,035,666
Stock-based compensation	$ 103		356,226			356,329
Balance (in shares) at Dec. 31, 2019	121,564,990
Balance at Dec. 31, 2019	$ 12,155		26,044,060		(25,120,233)	935,982
Balance (in shares) at Mar. 31, 2019	90,759,324
Balance at Mar. 31, 2019	$ 9,075		18,701,211		(19,491,866)	(781,580)
Sale of common stock, net of issuance fees (in shares)	29,770,000
Sale of common stock, net of issuance fees	$ 2,977		6,986,623			6,989,600
Net loss					(1,368,011)	(1,368,011)
Balance (in shares) at Jun. 30, 2019	120,529,324
Balance at Jun. 30, 2019	$ 12,052		25,687,834		(20,859,877)	4,840,009
Balance (in shares) at Dec. 31, 2019	121,564,990
Balance at Dec. 31, 2019	$ 12,155		26,044,060		(25,120,233)	935,982
Net loss					(2,633,992)	(2,633,992)
Balance (in shares) at Mar. 31, 2020	121,564,990
Balance at Mar. 31, 2020	$ 12,155		26,044,060		(27,754,225)	(1,698,010)
Balance (in shares) at Dec. 31, 2019	121,564,990
Balance at Dec. 31, 2019	$ 12,155		26,044,060		(25,120,233)	935,982
Net loss						(4,826,384)
Balance (in shares) at Jun. 30, 2020	141,564,990
Balance at Jun. 30, 2020	$ 14,155		28,012,423		(29,946,617)	(1,920,039)
Balance (in shares) at Mar. 31, 2020	121,564,990
Balance at Mar. 31, 2020	$ 12,155		26,044,060		(27,754,225)	(1,698,010)
Sale of common stock, net of issuance fees (in shares)	20,000,000
Sale of common stock, net of issuance fees	$ 2,000		1,968,363			1,970,363
Net loss					(2,192,392)	(2,192,392)
Balance (in shares) at Jun. 30, 2020	141,564,990
Balance at Jun. 30, 2020	$ 14,155		$ 28,012,423		$ (29,946,617)	$ (1,920,039)

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (7,532,533)	$ (4,255,033)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,681	10,124
Accrued stock compensation to employees	19,340	19,400
Accrued stock compensation to nonemployees	61,030	64,020
Issuance of stock-based compensation	356,329
Inventory valuation allowance	13,265	12,150
Increase or decrease in:
Accounts receivable	(63,385)	(23,184)
Inventory	160,636	42,540
Prepaid clinical expenses	(612,161)
Prepaid insurance and services	(118,884)	42,661
Other	2,162
Accounts payable and accrued expenses	1,119,033	898,882
Total adjustments	943,046	1,066,593
NET CASH USED IN OPERATING ACTIVITIES	(6,589,487)	(3,188,440)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of furniture and equipment	(1,324)	(2,959)
Proceeds from mortgage note receivable	37,456	35,899
NET CASH PROVIDED BY INVESTING ACTIVITIES	36,132	32,940
CASH FLOWS FROM FINANCING ACTIVITIES
Collection of stock subscription receivable	130,062
Proceeds from sale of common stock, preferred stock and warrants, net of issuance costs	6,989,600	4,101,939
NET CASH PROVIDED BY FINANCING ACTIVITIES	7,119,662	4,101,939
NET INCREASE IN CASH AND CASH EQUIVALENTS	566,307	946,439
CASH AND CASH EQUIVALENTS, beginning of year	2,217,412	1,270,973
CASH AND CASH EQUIVALENTS, end of year	2,783,719	2,217,412
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest
Cash paid for income taxes
NONCASH INVESTING AND FINANCING ACTIVITIES
Capitalization of right-to-use asset and lease liability	68,022
Common stock issued in exchange for a subscription receivable		130,062
Conversion of preferred stock into common stock		$ 1,424

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	( 1 The following is a summary of the more significant accounting policies of Cyclo Therapeutics, Inc . (a) ORGANIZATION AND OPERATIONS–– The Company was incorporated in August 1990 July 1992. 2000, September 2019 ® ® January 2017 ® September 2017. October 2019, May 2020 ® We also filed Clinical Trial Applications with several European regulatory bodies, including those in the United Kingdom, Sweden and Italy, and in Israel, all of which have approved our applications. The first July 2017, February 2020, 12 May 2020 ® 1500 2000 2500 February 2020 ® In addition, we are exploring the use of cyclodextrins in the treatment of Alzheimer's disease, and in October 2019 ® We also sell cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. However, our core business has transitioned to a biotechnology company primarily focused on the development of cyclodextrin-based biopharmaceuticals for the treatment of disease from a business which had been primarily reselling basic cyclodextrin products. (b) BASIS OF PRESENTATION––The consolidated financial statements include the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The interim consolidated financial statements of the Company included in this Quarterly Report on Form 10 not 10 December 31, 2019. 10 not (c) CASH AND CASH EQUIVALENTS––Cash and cash equivalents consist of cash and any highly liquid investments with an original purchased maturity of three (d) ACCOUNTS RECEIVABLE––Accounts receivable are unsecured and non-interest bearing and stated at the amount we expect to collect from outstanding balances. Customer account balances with invoices dated over 90 not The carrying amount of accounts receivable are reduced by an allowance for credit losses that reflects management's best estimate of the amounts that will not 90 not not June 30, 2020 December 31, 2019. (e) INVENTORY AND COST OF PRODUCTS SOLD––Inventory consists of our pharmaceutical drug Trappsol ® first first not $52,922 June 30, 2020 December 31, 2019, (f) PREPAID CLINICAL EXPENSES––Prepaid clinical expenses consist of our pharmaceutical drug Trappsol ® (g) MORTGAGE NOTE RECEIVABLE––The mortgage note receivable is stated at amortized value, which is the amount we expect to collect. (h) FURNITURE AND EQUIPMENT––Furniture and equipment are recorded at cost, less accumulated depreciation. Depreciation is computed using primarily the straight-line method over the estimated useful lives of the assets (generally three five seven ten may not (i) REVENUE RECOGNITION––Under the revenue standards of ASC 606, five No. 2014 09: Product revenues third Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the carrier. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one one Reserves for Discounts and Allowances Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration typically utilize the most likely method and reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may not may 2, (j) SHIPPING AND HANDLING FEES––Shipping and handling fees, if billed to customers, are included in product sales. Shipping and handling costs associated with inbound and outbound freight are expensed as incurred and included in freight and shipping expense. (k) ADVERTISING––Advertising costs are charged to operations when incurred. We incur minimal advertising expenses. (l) RESEARCH AND DEVELOPMENT COSTS––Research and development costs are expensed as incurred. (m) INCOME TAXES––Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In addition, tax benefits related to positions considered uncertain are recognized only when it is more likely than not 50% (n) NET LOSS PER COMMON SHARE––Basic and fully diluted net loss per common share is computed using a simple weighted average of common shares outstanding during the periods presented, as outstanding warrants to purchase 65,311,724 three six June 30, 2020 2019. (o) STOCK BASED COMPENSATION–– The Company periodically awards stock to employees, directors, and consultants. In the case of employees and consultants, an expense is recognized equal to the fair value of the stock determined using the closing trading price of the stock on the award date. With respect to directors, the Company accrues stock compensation expense on a quarterly basis based on the Company's historical director compensation policies, and each quarter recognizes such expense based on the trading price of the common stock during such quarter. (p) FAIR VALUE MEASUREMENTS AND DISCLOSURES––The Fair Value Measurements and Disclosures topic of the Accounting Standards Codification (“ASC”) requires companies to determine fair value based on the price that would be received to sell the asset or paid to transfer the liability to a market participant. The Fair Value Measurements and Disclosures topic emphasizes that fair value is a market-based measurement, not The guidance requires that assets and liabilities carried at fair value be classified and disclosed in one ● Level 1: ● Level 2: ● Level 3: not We have no June 30, 2020 December 31, 2019. For short-term classes of our financial instruments, which include cash, accounts receivable and accounts payable, and which are not June 30, 2020 December 31, 2019, (q) LIQUIDITY AND GOING CONCERN––For the six June 30, 2020 December 31, 2019, $4,826,000 $7,533,000, $29,946,000 June 30, 2020. ® ® For the six June 30, 2020, $3,870,000 June 30, 2020, $1,008,000 $1,969,000. The Company has incurred losses from operations in each of the last six may Our consolidated financial statements for the three six June 30, 2020 December 31, 2019 five not (r) USE OF ESTIMATES––The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions, including regarding contingencies, that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company's most significant estimate relates to inventory obsolescence. Although management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, actual results could significantly differ from these estimates. (s) RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS–– In June 2016, 2016 13, 326 December 15, 2022, not In December 2019, 2019 12, Simplifying the Accounting for Income Taxes. 2019 12 2019 12 December 15, 2020. not (t) UNCERTAINTY–– The recent outbreak of the COVID- 19 19 may may not 19 19 not 19, 19 9.	( 1 The following is a summary of the more significant accounting policies of Cyclo Therapeutics, Inc . (a) ORGANIZATION AND OPERATIONS––The Company was incorporated in August 1990 July 1992. 2000, September 2019 ® ® January 2017 ® September 2017. October 2019, second 2020. first July 2017, February 2020, 12 October 2019 ® We also sell cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. However, our core business has transitioned to a biotechnology company primarily focused on the development of cyclodextrin-based biopharmaceuticals for the treatment of disease from a business which had been primarily reselling basic cyclodextrin products. (b) BASIS OF PRESENTATION––The consolidated financial statements include the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. (c) CASH AND CASH EQUIVALENTS––Cash and cash equivalents consist of cash and any highly liquid investments with an original purchased maturity of three (d) ACCOUNTS RECEIVABLE––Accounts receivable are unsecured and non-interest bearing and stated at the amount we expect to collect from outstanding balances. Customer account balances with invoices dated over 90 not The carrying amount of accounts receivable are reduced by an allowance for credit losses that reflects management's best estimate of the amounts that will not 90 not not December 31, 2019 2018. (e) INVENTORY AND COST OF PRODUCTS SOLD––Inventory consists of our pharmaceutical drug Trappsol ® first first not $52,900 $39,700 December 31, 2019 2018, (f) PREPAID CLINICAL EXPENSES––Prepaid clinical expenses consist of our pharmaceutical drug Trappsol ® (g) MORTGAGE NOTE RECEIVABLE––The mortgage note receivable is stated at amortized value, which is the amount we expect to collect. (h) FURNITURE AND EQUIPMENT––Furniture and equipment are recorded at cost, less accumulated depreciation. Depreciation is computed using primarily the straight-line method over the estimated useful lives of the assets (generally three five seven ten may not (i) REVENUE RECOGNITION––Effective January 1, 2018, 606 January 1, 2018 not not no Under the new revenue standards, revenues are recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five No. 2014 09: Product revenues In the U.S. we sell our products to the end user or wholesale distributors. In other countries, we sell our products primarily to wholesale distributors and other third Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one one Reserves for Discounts and Allowances Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration typically utilize the most likely method and reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may not may For additional information on our revenues, please read Note 2, (j) SHIPPING AND HANDLING FEES––Shipping and handling fees, if billed to customers, are included in product sales. Shipping and handling costs associated with inbound and outbound freight are expensed as incurred and included in freight and shipping expense. (k) ADVERTISING––Advertising costs are charged to operations when incurred. We incur minimal advertising expenses. (l) RESEARCH AND DEVELOPMENT COSTS––Research and development costs are expensed as incurred. (m) INCOME TAXES––Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In addition, tax benefits related to positions considered uncertain are recognized only when it is more likely than not 50% The Tax Cut and Jobs Act (the “Tax Act”) was enacted on December 22, 2017. 35% 21%. 80% January 1, 2018. (n) NET LOSS PER COMMON SHARE––Basic and fully diluted net loss per common share is computed using a simple weighted average of common shares outstanding during the periods presented, as convertible preferred stock and outstanding warrants to purchase 63,321,294 32,192,294 2019 2018, (o) STOCK BASED COMPENSATION––The Company periodically awards stock to employees, directors, and consultants. An expense is recognized equal to the fair value of the stock determined using the closing trading price of the stock on the award date. (p) FAIR VALUE MEASUREMENTS AND DISCLOSURES––The Fair Value Measurements and Disclosures topic of the Accounting Standards Codification (“ASC”) requires companies to determine fair value based on the price that would be received to sell the asset or paid to transfer the liability to a market participant. The Fair Value Measurements and Disclosures topic emphasizes that fair value is a market-based measurement, not The guidance requires that assets and liabilities carried at fair value be classified and disclosed in one ● Level 1: ● Level 2: ● Level 3: not We have no December 31, 2019 2018. For short-term classes of our financial instruments, which include cash, accounts receivable and accounts payable, and which are not December 31, 2019 2018, (q) LIQUIDITY AND GOING CONCERN––For the years ended December 31, 2019 2018, $7,533,000 $4,255,000, $25,120,000 December 31, 2019. ® ® For year ended December 31, 2019, $6,589,000 $7,120,000 December 31, 2019, $2,784,000 $817,000. The Company has incurred losses from operations in each of the last six may Our consolidated financial statements for the years ended December 31, 2019 2018 five not (r) USE OF ESTIMATES––The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company's most significant estimate relates to inventory obsolescence. Although management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, actual results could significantly differ from these estimates. (s) RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS––In February 2016, 2016 02, 842 12 December 15, 2018, 842 January 1, 2019. 7. In December 2019, 2019 12, Simplifying the Accounting for Income Taxes. 2019 12 2019 12 December 15, 2020. not

Note 2 - Revenues

Note 2 - Revenues	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	( 2 ) REVENUES: The Company operates in one ® The Company considers there to be revenue concentration risks for regions where net product revenues exceed 10% may Revenues by product are summarized as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 20 20 20 19 Trappsol ® $ - $ - $ 30,096 $ 25,971 Trappsol ® 151,188 135,878 366,150 206,746 Trappsol ® 55,631 39,100 133,740 104,952 Aquaplex ® 928 97,130 928 149,690 Other 1,847 987 4,414 6,562 Total revenues $ 209,594 $ 273,095 $ 535,328 $ 493,921 Substantially all of our sales of Trappsol ® six June 30, 2020 December 31, 2019 ® six June 30, 2020 December 31, 2019 three	( 2 The Company operates in one 10% may 606 January 1, 2018 1 Revenues by product are summarized as follows: Year Ended December 31, 2019 2018 Trappsol ® $ 103,596 $ 166,596 Trappsol ® 481,379 484,101 Trappsol ® 265,947 233,910 Aquaplex ® 149,878 116,806 Other 6,398 10,064 Total revenues $ 1,007,198 $ 1,011,477 Substantially all of our sales of Trappsol ® December 31, 2019 2018 ® one

Note 3 - Major Customers and Su

Note 3 - Major Customers and Suppliers	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Major Customers and Suppliers Disclosure [Text Block]	( 3 ) MAJOR CUSTOMERS AND SUPPLIERS: Our revenues are derived primarily from chemical supply and pharmaceutical companies located primarily in the United States. For the six June 30, 2020 two 60% six June 30, 2019, four 65% Substantially all inventory purchases were from three 2020 2019. We have three ® ® For the six June 30, 2020, 6% 94% six June 30, 2019 6% 63% 30%	( 3 Our revenues are derived primarily from chemical supply and pharmaceutical companies located primarily in the United States. In 2019, four 70% 95% December 31, 2019. 2018, four 57% 31% December 31, 2018. Substantially all inventory purchases were from three 2019 2018. We have three ® ® For the year ended December 31, 2019, 10% 75% 15% December 31, 2018, 17% 71% 12%

Note 4 - Mortgage Note Receivab

Note 4 - Mortgage Note Receivable	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	( 4 ) MORTGAGE NOTE RECEIVABLE On January 21, 2016, $10,000 $265,000, $3,653, 4.25%, seven March 1, 2016, February 2023.	( 4 On January 21, 2016, $10,000 $265,000, $3,653, 4.25%, seven March 1, 2016, February 2023. Year Ending December 31, Principal 2020 $ 39,061 2021 40,754 2022 42,520 2023 7,322 $ 129,657

Note 5 - Equity Transactions

Note 5 - Equity Transactions	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	( 5 ) EQUITY TRANSACTIONS: The Company expensed $6,840 $14,060 three six June 30, 2020. $36,540 $67,930 three six June 30, 2019. not On May 31, 2019, 29,770,000 $0.25, one one $7,442,500, $452,900 $6,989,600. $0.30 66 th $452,900 1,359,000 July 12, 2019. not 270 365 120 Pursuant to terms of the Placement Agency Agreement between the Company and ThinkEquity, a division of Fordham Financial Management, Inc. (“ThinkEquity”), entered into in connection with Company's May 2019 “May $29,637, 8% first May 222,282 6% $0.11 110% On April 24, 2020, 20 $0.10 $2,000,000. As of June 30, 2020, 63,543,576 $0.11 $1.00 2025. seven June 30, 2020 480,000 May 2016 $0.25 164,074 February 2017 $0.35 600 October 2017 $100	( 8 The Company expensed $168,120 $83,420 2019 2018, not 2019, 450,000 $87,750, 241,666 $109,908. 344,000 2019 $158,670 172,000 2018 172,000 2017. 2018, not In April 2014, one 6% seven 6% 100% 2017, one June 2019. In April 2018, 20,100 $100 $2,010,000. one 400 seven 400 $0.25 March 31, 2018, $74,983 $50,000. On May 23, 2018, 100,000,000 500,000,000 no 400 14,240,000. In December 2018, 3,519,963 $0.65 $2,342,034, $130,063 January 2019 one seven one $0.65 On May 31, 2019, 29,770,000 $0.25, one one $7,442,500, $452,900 $6,989,600. $0.30 66 th $452,900 1,359,000 July 12, 2019. not 270 365 120 The following table presents the number of Common Stock warrants outstanding: Warrants outstanding, December 31, 2017 20,632,331 Issued 11,559,963 Exercised - Expired - Warrants outstanding, December 31, 2018 32,192,294 Issued 31,129,000 Exercised - Expired - Warrants outstanding, December 31, 2019 63,321,294 The following table presents the number of Common Stock warrants outstanding, their exercise price, and expiration dates at December 31, 2019: Warrants Issued Exercise Price Expiration Date 240,000 $ 0.25 April 2021 103,500 $ 1.00 July 2021 156,000 $ 0.50 July 2022 78,000 $ 0.50 August 2022 8,100,000 $ 0.25 June 2023 5,754,831 $ 0.35 February 2024 6,200,000 $ 0.25 October 2024 31,129,000 $ 0.30 November 2024 8,040,000 $ 0.25 April 2025 3,519,963 $ 0.65 December 2025 63,321,294 In addition, there are seven December 31, 2019 480,000 May 2016 $0.25 164,074 February 2017 $0.35 600 October 2017 $100

Note 6 - Income Taxes

Note 6 - Income Taxes	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	( 6 ) INCOME TAXES: The Company reported a net loss for the three six June 30, 2020 2019,	( 10 If all of our net operating loss carryforwards and temporary deductible differences were used, we would realize a net deferred tax asset of approximately $8,881,000 740, not December 31, 2019, not not 100% Positive evidence we evaluated in the order of significance and weighting in our evaluation includes the amount of net operating loss carryforward utilized against current income tax liabilities in four ten We have available at December 31, 2019, $18,335,000 may If not Year Ending December 31, Amount 2020 $ 174,000 2021 71,000 2024 66,000 2028 7,000 2030 160,000 2031 73,000 2032 48,000 2034 727,000 2035 1,969,000 2036 2,867,000 2037 2,481,000 Indefinite 9,692,000 Total $ 18,335,000 A change in ownership pursuant to Section 382 2014. 382 December 31, 2019, 382 not The Company has expenses that qualify for the Orphan Drug Credit. The Orphan Drug Credit may may 20 not 20 $4,292,000 December 31, 2019. For 2019, not $2,645,000 2018 2019, 2019. For 2018, not $1,575,000 2017 2018, 2018. Significant components of our deferred Federal income taxes were as follows: 2019 2018 Deferred tax assets: Net operating loss carryforwards $ 4,496,000 $ 3,017,000 Tax credits 4,292,000 3,085,000 Impairment allowances 13,000 10,000 Stock-based compensation 20,000 64,000 Other 62,000 62,000 Less valuation allowance (8,881,000 ) (6,235,000 ) Deferred tax asset, net of valuation 2,000 3,000 Deferred tax liabilities: Property and equipment (2,000 ) (3,000 ) Deferred tax liabilities (2,000 ) (3,000 ) Net tax assets $ - $ - On December 22, 2017, 1 34% 21%, January 1, 2018. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company's net tax asset as of December 31, 2018 34% 21% 34% January 1, 2018. $768,000. January 1, 2019, 5.5% 4.458%. $102,000. The differences between the effective income tax rate reflected in the benefit (provision) for income taxes and the amounts, which would be determined by applying federal statutory income tax rate of 21% December 31, 2019 2018, 2019 2018 Tax benefit (expense) at Federal statutory rate $ 1,582,000 $ 894,000 Effect of State taxes 265,000 185,000 Effect of tax rate change (102,000 ) - Tax credits 1,217,000 676,000 Nondeductible expenses (317,000 ) (180,000 ) Valuation allowance – deferred tax assets (2,645,000 ) (1,575,000 ) Total tax benefit (provision) $ - $ - The Company files income tax returns in the U.S. Federal jurisdiction, and in the State of Florida. The Company is no 2016. The Company has reviewed and evaluated the relevant technical merits of each of its tax positions in accordance with accounting principles generally accepted in the United States of America for accounting for uncertainty in income taxes, and determined that there are no

Note 7 - Equity Incentive Plan

Note 7 - Equity Incentive Plan	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Equity Incentive Plan Disclosure [Text Block]	( 7 ) EQUITY INCENTIVE PLAN: On August 29, 2019, 2019 6,843,750 may 1986, may not ten June 30, 2020, 450,000 6,393,750	( 12 On August 29, 2019, 2019 6,843,750 may 1986, may not ten December 31, 2019, 450,000 6,393,750

Note 8 - Leases

Note 8 - Leases	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	( 8 ) LEASES : The Company adopted ASU 2016 02 Leases 842 2019, not 840, Under the new guidance, right-of-use assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease terms at the commencement dates. The Company uses its incremental borrowing rates as the discount rate for its leases, which is equal to the rate of interest the Company would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The incremental borrowing rate for all existing leases as of the opening balance sheet date was based upon the remaining terms of the leases; the incremental borrowing rate for all new or amended leases is based upon the lease terms. The lease terms for all the Company's leases include the contractually obligated period of the leases, plus any additional periods covered by a Company options to extend the leases that the Company is reasonably certain to exercise. The Company has elected the package of practical expedients permitted under the transition guidance, which among other things, allows us to carryforward our prior lease classifications under ASC 840, Adoption of Topic 842 not The Company determines if an arrangement is or contains a lease at contract inception and recognizes a right-of-use asset and a lease liability at the lease commencement date. Leases with an initial term of 12 one not 842. Certain leases provide that the lease payments may not not The Company has one Operating lease assets are recorded net of accumulated amortization of $25,507 June 30, 2020. six June 30, 2020 2019 $8,929 $11,376.	( 7 The Company adopted ASU 2016 02 Leases 842 2019, no December 31, 2018. not 840, Under the new guidance, right-of-use assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease terms at the commencement dates. The Company uses its incremental borrowing rates as the discount rate for its leases, which is equal to the rate of interest the Company would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The incremental borrowing rate for all existing leases as of the opening balance sheet date was based upon the remaining terms of the leases; the incremental borrowing rate for all new or amended leases is based upon the lease terms. The lease terms for all the Company's leases include the contractually obligated period of the leases, plus any additional periods covered by a Company options to extend the leases that the Company is reasonably certain to exercise The Company has elected the package of practical expedients permitted under the transition guidance, which among other things, allows us to carryforward our prior lease classifications under ASC 840, Adoption of Topic 842 not The effects of the changes made to the Company's consolidated balance sheet as of December 31, 2018 842 The Company determines if an arrangement is or contains a lease at contract inception and recognizes a right-of-use asset and a lease liability at the lease commencement date. Leases with an initial term of 12 one not 842. Certain leases provide that the lease payments may not not The Company has one Operating lease assets are recorded net of accumulated amortization of $17,006 December 31, 2019. December 31, 2019 2018 $17,006 $22,249, The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of December 31, 2019: Year ending December 31, Amounts 2020 $ 19,170 2021 19,170 2022 19,170 2023 1,598 2024 - Total $ 59,108

Note 9 - Note Payable

Note 9 - Note Payable	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	( 9 ) NOTE PAYABLE : On May 4, 2020, $158,524 May 4, 2022 1% December 4, 2020. may Year Ending December 31, Amount 2020 $ 7,994 2021 $ 106,035 2022 $ 44,495 Total $ 158,524

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	( 1 The following is a summary of the more significant accounting policies of Cyclo Therapeutics, Inc . (a) ORGANIZATION AND OPERATIONS–– The Company was incorporated in August 1990 July 1992. 2000, September 2019 ® ® January 2017 ® September 2017. October 2019, May 2020 ® We also filed Clinical Trial Applications with several European regulatory bodies, including those in the United Kingdom, Sweden and Italy, and in Israel, all of which have approved our applications. The first July 2017, February 2020, 12 May 2020 ® 1500 2000 2500 February 2020 ® In addition, we are exploring the use of cyclodextrins in the treatment of Alzheimer's disease, and in October 2019 ® We also sell cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. However, our core business has transitioned to a biotechnology company primarily focused on the development of cyclodextrin-based biopharmaceuticals for the treatment of disease from a business which had been primarily reselling basic cyclodextrin products. (b) BASIS OF PRESENTATION––The consolidated financial statements include the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The interim consolidated financial statements of the Company included in this Quarterly Report on Form 10 not 10 December 31, 2019. 10 not (c) CASH AND CASH EQUIVALENTS––Cash and cash equivalents consist of cash and any highly liquid investments with an original purchased maturity of three (d) ACCOUNTS RECEIVABLE––Accounts receivable are unsecured and non-interest bearing and stated at the amount we expect to collect from outstanding balances. Customer account balances with invoices dated over 90 not The carrying amount of accounts receivable are reduced by an allowance for credit losses that reflects management's best estimate of the amounts that will not 90 not not June 30, 2020 December 31, 2019. (e) INVENTORY AND COST OF PRODUCTS SOLD––Inventory consists of our pharmaceutical drug Trappsol ® first first not $52,922 June 30, 2020 December 31, 2019, (f) PREPAID CLINICAL EXPENSES––Prepaid clinical expenses consist of our pharmaceutical drug Trappsol ® (g) MORTGAGE NOTE RECEIVABLE––The mortgage note receivable is stated at amortized value, which is the amount we expect to collect. (h) FURNITURE AND EQUIPMENT––Furniture and equipment are recorded at cost, less accumulated depreciation. Depreciation is computed using primarily the straight-line method over the estimated useful lives of the assets (generally three five seven ten may not (i) REVENUE RECOGNITION––Under the revenue standards of ASC 606, five No. 2014 09: Product revenues third Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the carrier. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one one Reserves for Discounts and Allowances Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration typically utilize the most likely method and reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may not may 2, (j) SHIPPING AND HANDLING FEES––Shipping and handling fees, if billed to customers, are included in product sales. Shipping and handling costs associated with inbound and outbound freight are expensed as incurred and included in freight and shipping expense. (k) ADVERTISING––Advertising costs are charged to operations when incurred. We incur minimal advertising expenses. (l) RESEARCH AND DEVELOPMENT COSTS––Research and development costs are expensed as incurred. (m) INCOME TAXES––Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In addition, tax benefits related to positions considered uncertain are recognized only when it is more likely than not 50% (n) NET LOSS PER COMMON SHARE––Basic and fully diluted net loss per common share is computed using a simple weighted average of common shares outstanding during the periods presented, as outstanding warrants to purchase 65,311,724 three six June 30, 2020 2019. (o) STOCK BASED COMPENSATION–– The Company periodically awards stock to employees, directors, and consultants. In the case of employees and consultants, an expense is recognized equal to the fair value of the stock determined using the closing trading price of the stock on the award date. With respect to directors, the Company accrues stock compensation expense on a quarterly basis based on the Company's historical director compensation policies, and each quarter recognizes such expense based on the trading price of the common stock during such quarter. (p) FAIR VALUE MEASUREMENTS AND DISCLOSURES––The Fair Value Measurements and Disclosures topic of the Accounting Standards Codification (“ASC”) requires companies to determine fair value based on the price that would be received to sell the asset or paid to transfer the liability to a market participant. The Fair Value Measurements and Disclosures topic emphasizes that fair value is a market-based measurement, not The guidance requires that assets and liabilities carried at fair value be classified and disclosed in one ● Level 1: ● Level 2: ● Level 3: not We have no June 30, 2020 December 31, 2019. For short-term classes of our financial instruments, which include cash, accounts receivable and accounts payable, and which are not June 30, 2020 December 31, 2019, (q) LIQUIDITY AND GOING CONCERN––For the six June 30, 2020 December 31, 2019, $4,826,000 $7,533,000, $29,946,000 June 30, 2020. ® ® For the six June 30, 2020, $3,870,000 June 30, 2020, $1,008,000 $1,969,000. The Company has incurred losses from operations in each of the last six may Our consolidated financial statements for the three six June 30, 2020 December 31, 2019 five not (r) USE OF ESTIMATES––The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions, including regarding contingencies, that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company's most significant estimate relates to inventory obsolescence. Although management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, actual results could significantly differ from these estimates. (s) RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS–– In June 2016, 2016 13, 326 December 15, 2022, not In December 2019, 2019 12, Simplifying the Accounting for Income Taxes. 2019 12 2019 12 December 15, 2020. not (t) UNCERTAINTY–– The recent outbreak of the COVID- 19 19 may may not 19 19 not 19, 19 9.	( 1 The following is a summary of the more significant accounting policies of Cyclo Therapeutics, Inc . (a) ORGANIZATION AND OPERATIONS––The Company was incorporated in August 1990 July 1992. 2000, September 2019 ® ® January 2017 ® September 2017. October 2019, second 2020. first July 2017, February 2020, 12 October 2019 ® We also sell cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. However, our core business has transitioned to a biotechnology company primarily focused on the development of cyclodextrin-based biopharmaceuticals for the treatment of disease from a business which had been primarily reselling basic cyclodextrin products. (b) BASIS OF PRESENTATION––The consolidated financial statements include the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. (c) CASH AND CASH EQUIVALENTS––Cash and cash equivalents consist of cash and any highly liquid investments with an original purchased maturity of three (d) ACCOUNTS RECEIVABLE––Accounts receivable are unsecured and non-interest bearing and stated at the amount we expect to collect from outstanding balances. Customer account balances with invoices dated over 90 not The carrying amount of accounts receivable are reduced by an allowance for credit losses that reflects management's best estimate of the amounts that will not 90 not not December 31, 2019 2018. (e) INVENTORY AND COST OF PRODUCTS SOLD––Inventory consists of our pharmaceutical drug Trappsol ® first first not $52,900 $39,700 December 31, 2019 2018, (f) PREPAID CLINICAL EXPENSES––Prepaid clinical expenses consist of our pharmaceutical drug Trappsol ® (g) MORTGAGE NOTE RECEIVABLE––The mortgage note receivable is stated at amortized value, which is the amount we expect to collect. (h) FURNITURE AND EQUIPMENT––Furniture and equipment are recorded at cost, less accumulated depreciation. Depreciation is computed using primarily the straight-line method over the estimated useful lives of the assets (generally three five seven ten may not (i) REVENUE RECOGNITION––Effective January 1, 2018, 606 January 1, 2018 not not no Under the new revenue standards, revenues are recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five No. 2014 09: Product revenues In the U.S. we sell our products to the end user or wholesale distributors. In other countries, we sell our products primarily to wholesale distributors and other third Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one one Reserves for Discounts and Allowances Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration typically utilize the most likely method and reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may not may For additional information on our revenues, please read Note 2, (j) SHIPPING AND HANDLING FEES––Shipping and handling fees, if billed to customers, are included in product sales. Shipping and handling costs associated with inbound and outbound freight are expensed as incurred and included in freight and shipping expense. (k) ADVERTISING––Advertising costs are charged to operations when incurred. We incur minimal advertising expenses. (l) RESEARCH AND DEVELOPMENT COSTS––Research and development costs are expensed as incurred. (m) INCOME TAXES––Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In addition, tax benefits related to positions considered uncertain are recognized only when it is more likely than not 50% The Tax Cut and Jobs Act (the “Tax Act”) was enacted on December 22, 2017. 35% 21%. 80% January 1, 2018. (n) NET LOSS PER COMMON SHARE––Basic and fully diluted net loss per common share is computed using a simple weighted average of common shares outstanding during the periods presented, as convertible preferred stock and outstanding warrants to purchase 63,321,294 32,192,294 2019 2018, (o) STOCK BASED COMPENSATION––The Company periodically awards stock to employees, directors, and consultants. An expense is recognized equal to the fair value of the stock determined using the closing trading price of the stock on the award date. (p) FAIR VALUE MEASUREMENTS AND DISCLOSURES––The Fair Value Measurements and Disclosures topic of the Accounting Standards Codification (“ASC”) requires companies to determine fair value based on the price that would be received to sell the asset or paid to transfer the liability to a market participant. The Fair Value Measurements and Disclosures topic emphasizes that fair value is a market-based measurement, not The guidance requires that assets and liabilities carried at fair value be classified and disclosed in one ● Level 1: ● Level 2: ● Level 3: not We have no December 31, 2019 2018. For short-term classes of our financial instruments, which include cash, accounts receivable and accounts payable, and which are not December 31, 2019 2018, (q) LIQUIDITY AND GOING CONCERN––For the years ended December 31, 2019 2018, $7,533,000 $4,255,000, $25,120,000 December 31, 2019. ® ® For year ended December 31, 2019, $6,589,000 $7,120,000 December 31, 2019, $2,784,000 $817,000. The Company has incurred losses from operations in each of the last six may Our consolidated financial statements for the years ended December 31, 2019 2018 five not (r) USE OF ESTIMATES––The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company's most significant estimate relates to inventory obsolescence. Although management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, actual results could significantly differ from these estimates. (s) RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS––In February 2016, 2016 02, 842 12 December 15, 2018, 842 January 1, 2019. 7. In December 2019, 2019 12, Simplifying the Accounting for Income Taxes. 2019 12 2019 12 December 15, 2020. not

Note 2 - Revenues 10K

Note 2 - Revenues 10K	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	( 2 ) REVENUES: The Company operates in one ® The Company considers there to be revenue concentration risks for regions where net product revenues exceed 10% may Revenues by product are summarized as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 20 20 20 19 Trappsol ® $ - $ - $ 30,096 $ 25,971 Trappsol ® 151,188 135,878 366,150 206,746 Trappsol ® 55,631 39,100 133,740 104,952 Aquaplex ® 928 97,130 928 149,690 Other 1,847 987 4,414 6,562 Total revenues $ 209,594 $ 273,095 $ 535,328 $ 493,921 Substantially all of our sales of Trappsol ® six June 30, 2020 December 31, 2019 ® six June 30, 2020 December 31, 2019 three	( 2 The Company operates in one 10% may 606 January 1, 2018 1 Revenues by product are summarized as follows: Year Ended December 31, 2019 2018 Trappsol ® $ 103,596 $ 166,596 Trappsol ® 481,379 484,101 Trappsol ® 265,947 233,910 Aquaplex ® 149,878 116,806 Other 6,398 10,064 Total revenues $ 1,007,198 $ 1,011,477 Substantially all of our sales of Trappsol ® December 31, 2019 2018 ® one

Note 3 - Major Customers and _2

Note 3 - Major Customers and Suppliers	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Major Customers and Suppliers Disclosure [Text Block]	( 3 ) MAJOR CUSTOMERS AND SUPPLIERS: Our revenues are derived primarily from chemical supply and pharmaceutical companies located primarily in the United States. For the six June 30, 2020 two 60% six June 30, 2019, four 65% Substantially all inventory purchases were from three 2020 2019. We have three ® ® For the six June 30, 2020, 6% 94% six June 30, 2019 6% 63% 30%	( 3 Our revenues are derived primarily from chemical supply and pharmaceutical companies located primarily in the United States. In 2019, four 70% 95% December 31, 2019. 2018, four 57% 31% December 31, 2018. Substantially all inventory purchases were from three 2019 2018. We have three ® ® For the year ended December 31, 2019, 10% 75% 15% December 31, 2018, 17% 71% 12%

Note 4 - Mortgage Note Receiv_2

Note 4 - Mortgage Note Receivable	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	( 4 ) MORTGAGE NOTE RECEIVABLE On January 21, 2016, $10,000 $265,000, $3,653, 4.25%, seven March 1, 2016, February 2023.	( 4 On January 21, 2016, $10,000 $265,000, $3,653, 4.25%, seven March 1, 2016, February 2023. Year Ending December 31, Principal 2020 $ 39,061 2021 40,754 2022 42,520 2023 7,322 $ 129,657

Note 5 - Concentrations of Cred

Note 5 - Concentrations of Credit Risk	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	( 5 Significant concentrations of credit risk for all financial instruments owned by the Company are as follows: DEMAND DEPOSITS––We maintain bank accounts in Federal credit unions and other financial institutions, which are insured up to the Federal Deposit Insurance Corporation limits. The bank accounts may not

Note 6 - Furniture and Equipmen

Note 6 - Furniture and Equipment	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	( 6 Furniture and equipment consists of the following as of December 31: 2019 2018 Machinery and equipment $ 16,524 $ 16,089 Office furniture 49,490 52,820 66,014 68,909 Less: accumulated depreciation 52,468 50,338 Furniture and equipment, net $ 13,546 $ 18,571

Note 7 - Leases

Note 7 - Leases	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	( 8 ) LEASES : The Company adopted ASU 2016 02 Leases 842 2019, not 840, Under the new guidance, right-of-use assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease terms at the commencement dates. The Company uses its incremental borrowing rates as the discount rate for its leases, which is equal to the rate of interest the Company would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The incremental borrowing rate for all existing leases as of the opening balance sheet date was based upon the remaining terms of the leases; the incremental borrowing rate for all new or amended leases is based upon the lease terms. The lease terms for all the Company's leases include the contractually obligated period of the leases, plus any additional periods covered by a Company options to extend the leases that the Company is reasonably certain to exercise. The Company has elected the package of practical expedients permitted under the transition guidance, which among other things, allows us to carryforward our prior lease classifications under ASC 840, Adoption of Topic 842 not The Company determines if an arrangement is or contains a lease at contract inception and recognizes a right-of-use asset and a lease liability at the lease commencement date. Leases with an initial term of 12 one not 842. Certain leases provide that the lease payments may not not The Company has one Operating lease assets are recorded net of accumulated amortization of $25,507 June 30, 2020. six June 30, 2020 2019 $8,929 $11,376.	( 7 The Company adopted ASU 2016 02 Leases 842 2019, no December 31, 2018. not 840, Under the new guidance, right-of-use assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease terms at the commencement dates. The Company uses its incremental borrowing rates as the discount rate for its leases, which is equal to the rate of interest the Company would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The incremental borrowing rate for all existing leases as of the opening balance sheet date was based upon the remaining terms of the leases; the incremental borrowing rate for all new or amended leases is based upon the lease terms. The lease terms for all the Company's leases include the contractually obligated period of the leases, plus any additional periods covered by a Company options to extend the leases that the Company is reasonably certain to exercise The Company has elected the package of practical expedients permitted under the transition guidance, which among other things, allows us to carryforward our prior lease classifications under ASC 840, Adoption of Topic 842 not The effects of the changes made to the Company's consolidated balance sheet as of December 31, 2018 842 The Company determines if an arrangement is or contains a lease at contract inception and recognizes a right-of-use asset and a lease liability at the lease commencement date. Leases with an initial term of 12 one not 842. Certain leases provide that the lease payments may not not The Company has one Operating lease assets are recorded net of accumulated amortization of $17,006 December 31, 2019. December 31, 2019 2018 $17,006 $22,249, The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of December 31, 2019: Year ending December 31, Amounts 2020 $ 19,170 2021 19,170 2022 19,170 2023 1,598 2024 - Total $ 59,108

Note 8 - Equity Transactions

Note 8 - Equity Transactions	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	( 5 ) EQUITY TRANSACTIONS: The Company expensed $6,840 $14,060 three six June 30, 2020. $36,540 $67,930 three six June 30, 2019. not On May 31, 2019, 29,770,000 $0.25, one one $7,442,500, $452,900 $6,989,600. $0.30 66 th $452,900 1,359,000 July 12, 2019. not 270 365 120 Pursuant to terms of the Placement Agency Agreement between the Company and ThinkEquity, a division of Fordham Financial Management, Inc. (“ThinkEquity”), entered into in connection with Company's May 2019 “May $29,637, 8% first May 222,282 6% $0.11 110% On April 24, 2020, 20 $0.10 $2,000,000. As of June 30, 2020, 63,543,576 $0.11 $1.00 2025. seven June 30, 2020 480,000 May 2016 $0.25 164,074 February 2017 $0.35 600 October 2017 $100	( 8 The Company expensed $168,120 $83,420 2019 2018, not 2019, 450,000 $87,750, 241,666 $109,908. 344,000 2019 $158,670 172,000 2018 172,000 2017. 2018, not In April 2014, one 6% seven 6% 100% 2017, one June 2019. In April 2018, 20,100 $100 $2,010,000. one 400 seven 400 $0.25 March 31, 2018, $74,983 $50,000. On May 23, 2018, 100,000,000 500,000,000 no 400 14,240,000. In December 2018, 3,519,963 $0.65 $2,342,034, $130,063 January 2019 one seven one $0.65 On May 31, 2019, 29,770,000 $0.25, one one $7,442,500, $452,900 $6,989,600. $0.30 66 th $452,900 1,359,000 July 12, 2019. not 270 365 120 The following table presents the number of Common Stock warrants outstanding: Warrants outstanding, December 31, 2017 20,632,331 Issued 11,559,963 Exercised - Expired - Warrants outstanding, December 31, 2018 32,192,294 Issued 31,129,000 Exercised - Expired - Warrants outstanding, December 31, 2019 63,321,294 The following table presents the number of Common Stock warrants outstanding, their exercise price, and expiration dates at December 31, 2019: Warrants Issued Exercise Price Expiration Date 240,000 $ 0.25 April 2021 103,500 $ 1.00 July 2021 156,000 $ 0.50 July 2022 78,000 $ 0.50 August 2022 8,100,000 $ 0.25 June 2023 5,754,831 $ 0.35 February 2024 6,200,000 $ 0.25 October 2024 31,129,000 $ 0.30 November 2024 8,040,000 $ 0.25 April 2025 3,519,963 $ 0.65 December 2025 63,321,294 In addition, there are seven December 31, 2019 480,000 May 2016 $0.25 164,074 February 2017 $0.35 600 October 2017 $100

Note 9 - Preferred Stock

Note 9 - Preferred Stock	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Preferred Stock [Text Block]	( 9 The Company's Articles of Incorporation provide for 5,000,000 December 31, 2019 2018, no In October 2017, 50,000 35,600 7 400 $100 not 2018. 7,

Note 10 - Income Taxes

Note 10 - Income Taxes	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	( 6 ) INCOME TAXES: The Company reported a net loss for the three six June 30, 2020 2019,	( 10 If all of our net operating loss carryforwards and temporary deductible differences were used, we would realize a net deferred tax asset of approximately $8,881,000 740, not December 31, 2019, not not 100% Positive evidence we evaluated in the order of significance and weighting in our evaluation includes the amount of net operating loss carryforward utilized against current income tax liabilities in four ten We have available at December 31, 2019, $18,335,000 may If not Year Ending December 31, Amount 2020 $ 174,000 2021 71,000 2024 66,000 2028 7,000 2030 160,000 2031 73,000 2032 48,000 2034 727,000 2035 1,969,000 2036 2,867,000 2037 2,481,000 Indefinite 9,692,000 Total $ 18,335,000 A change in ownership pursuant to Section 382 2014. 382 December 31, 2019, 382 not The Company has expenses that qualify for the Orphan Drug Credit. The Orphan Drug Credit may may 20 not 20 $4,292,000 December 31, 2019. For 2019, not $2,645,000 2018 2019, 2019. For 2018, not $1,575,000 2017 2018, 2018. Significant components of our deferred Federal income taxes were as follows: 2019 2018 Deferred tax assets: Net operating loss carryforwards $ 4,496,000 $ 3,017,000 Tax credits 4,292,000 3,085,000 Impairment allowances 13,000 10,000 Stock-based compensation 20,000 64,000 Other 62,000 62,000 Less valuation allowance (8,881,000 ) (6,235,000 ) Deferred tax asset, net of valuation 2,000 3,000 Deferred tax liabilities: Property and equipment (2,000 ) (3,000 ) Deferred tax liabilities (2,000 ) (3,000 ) Net tax assets $ - $ - On December 22, 2017, 1 34% 21%, January 1, 2018. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company's net tax asset as of December 31, 2018 34% 21% 34% January 1, 2018. $768,000. January 1, 2019, 5.5% 4.458%. $102,000. The differences between the effective income tax rate reflected in the benefit (provision) for income taxes and the amounts, which would be determined by applying federal statutory income tax rate of 21% December 31, 2019 2018, 2019 2018 Tax benefit (expense) at Federal statutory rate $ 1,582,000 $ 894,000 Effect of State taxes 265,000 185,000 Effect of tax rate change (102,000 ) - Tax credits 1,217,000 676,000 Nondeductible expenses (317,000 ) (180,000 ) Valuation allowance – deferred tax assets (2,645,000 ) (1,575,000 ) Total tax benefit (provision) $ - $ - The Company files income tax returns in the U.S. Federal jurisdiction, and in the State of Florida. The Company is no 2016. The Company has reviewed and evaluated the relevant technical merits of each of its tax positions in accordance with accounting principles generally accepted in the United States of America for accounting for uncertainty in income taxes, and determined that there are no

Note 11 - Employee Benefit Plan

Note 11 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Retirement Benefits [Text Block]	( 11 The Company maintains a 401 may may 2019 2018, not 4% 401 $29,410 $24,765 2019 2018,

Note 12 - Equity Incentive Plan

Note 12 - Equity Incentive Plan	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Equity Incentive Plan Disclosure [Text Block]	( 7 ) EQUITY INCENTIVE PLAN: On August 29, 2019, 2019 6,843,750 may 1986, may not ten June 30, 2020, 450,000 6,393,750	( 12 On August 29, 2019, 2019 6,843,750 may 1986, may not ten December 31, 2019, 450,000 6,393,750

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	( 13 From time to time, the Company is a party to claims and legal proceedings arising in the ordinary course of business. Our management evaluates our exposure to these claims and proceedings individually and in the aggregate and records an expense for potential losses on such litigation if it is possible to estimate the amount of loss and if the amount of the loss is probable. On November 26, 2018, two 2,500 $1,600 two

Note 14 - Related Party Transac

Note 14 - Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	( 14 As discussed in Note 7 June 2019. Since October 2016, $5,000 one In June 2019, $125,000. 50,000 September 2019. During 2017, $5,000 January May 2019, $5,800 June 2019, $69,600. 25,000 September 2019. Kevin J. Strattan, the son of C.E. Rick Strattan, has been employed by us since 2008, 2014 $100,000 $107,200 October 2018. $10,000 $12,500 2018 2019, 50,000 September 2019. Corey E. Strattan, the daughter-in-law of C.E. Rick Strattan, has been employed by us since 2011 $72,000 2018, $78,000 2019. $5,000 2018. 25,000 September 2019.

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Organization and Operations [Policy Text Block]	(a) ORGANIZATION AND OPERATIONS–– The Company was incorporated in August 1990 July 1992. 2000, September 2019 ® ® January 2017 ® September 2017. October 2019, May 2020 ® We also filed Clinical Trial Applications with several European regulatory bodies, including those in the United Kingdom, Sweden and Italy, and in Israel, all of which have approved our applications. The first July 2017, February 2020, 12 May 2020 ® 1500 2000 2500 February 2020 ® In addition, we are exploring the use of cyclodextrins in the treatment of Alzheimer's disease, and in October 2019 ® We also sell cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. However, our core business has transitioned to a biotechnology company primarily focused on the development of cyclodextrin-based biopharmaceuticals for the treatment of disease from a business which had been primarily reselling basic cyclodextrin products.	(a) ORGANIZATION AND OPERATIONS––The Company was incorporated in August 1990 July 1992. 2000, September 2019 ® ® January 2017 ® September 2017. October 2019, second 2020. first July 2017, February 2020, 12 October 2019 ® We also sell cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. However, our core business has transitioned to a biotechnology company primarily focused on the development of cyclodextrin-based biopharmaceuticals for the treatment of disease from a business which had been primarily reselling basic cyclodextrin products.
Basis of Accounting, Policy [Policy Text Block]	(b) BASIS OF PRESENTATION––The consolidated financial statements include the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The interim consolidated financial statements of the Company included in this Quarterly Report on Form 10 not 10 December 31, 2019. 10 not	(b) BASIS OF PRESENTATION––The consolidated financial statements include the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Cash and Cash Equivalents, Policy [Policy Text Block]	(c) CASH AND CASH EQUIVALENTS––Cash and cash equivalents consist of cash and any highly liquid investments with an original purchased maturity of three	(c) CASH AND CASH EQUIVALENTS––Cash and cash equivalents consist of cash and any highly liquid investments with an original purchased maturity of three
Receivable [Policy Text Block]	(d) ACCOUNTS RECEIVABLE––Accounts receivable are unsecured and non-interest bearing and stated at the amount we expect to collect from outstanding balances. Customer account balances with invoices dated over 90 not The carrying amount of accounts receivable are reduced by an allowance for credit losses that reflects management's best estimate of the amounts that will not 90 not not June 30, 2020 December 31, 2019.	(d) ACCOUNTS RECEIVABLE––Accounts receivable are unsecured and non-interest bearing and stated at the amount we expect to collect from outstanding balances. Customer account balances with invoices dated over 90 not The carrying amount of accounts receivable are reduced by an allowance for credit losses that reflects management's best estimate of the amounts that will not 90 not not December 31, 2019 2018.
Inventory, Cash Flow Policy [Policy Text Block]	(e) INVENTORY AND COST OF PRODUCTS SOLD––Inventory consists of our pharmaceutical drug Trappsol ® first first not $52,922 June 30, 2020 December 31, 2019,	(e) INVENTORY AND COST OF PRODUCTS SOLD––Inventory consists of our pharmaceutical drug Trappsol ® first first not $52,900 $39,700 December 31, 2019 2018,
Prepaid Expenses [Policy Text Block]	(f) PREPAID CLINICAL EXPENSES––Prepaid clinical expenses consist of our pharmaceutical drug Trappsol ®	(f) PREPAID CLINICAL EXPENSES––Prepaid clinical expenses consist of our pharmaceutical drug Trappsol ®
Mortgage Banking Activity [Policy Text Block]	(g) MORTGAGE NOTE RECEIVABLE––The mortgage note receivable is stated at amortized value, which is the amount we expect to collect.	(g) MORTGAGE NOTE RECEIVABLE––The mortgage note receivable is stated at amortized value, which is the amount we expect to collect.
Property, Plant and Equipment, Policy [Policy Text Block]	(h) FURNITURE AND EQUIPMENT––Furniture and equipment are recorded at cost, less accumulated depreciation. Depreciation is computed using primarily the straight-line method over the estimated useful lives of the assets (generally three five seven ten may not	(h) FURNITURE AND EQUIPMENT––Furniture and equipment are recorded at cost, less accumulated depreciation. Depreciation is computed using primarily the straight-line method over the estimated useful lives of the assets (generally three five seven ten may not
Revenue [Policy Text Block]	(i) REVENUE RECOGNITION––Under the revenue standards of ASC 606, five No. 2014 09: Product revenues third Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the carrier. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one one Reserves for Discounts and Allowances Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration typically utilize the most likely method and reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may not may 2,	(i) REVENUE RECOGNITION––Effective January 1, 2018, 606 January 1, 2018 not not no Under the new revenue standards, revenues are recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five No. 2014 09: Product revenues In the U.S. we sell our products to the end user or wholesale distributors. In other countries, we sell our products primarily to wholesale distributors and other third Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one one Reserves for Discounts and Allowances Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration typically utilize the most likely method and reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may not may For additional information on our revenues, please read Note 2,
Revenue from Contract with Customer, Shipping and Handling Fees, Policy [Policy Text Block]	(j) SHIPPING AND HANDLING FEES––Shipping and handling fees, if billed to customers, are included in product sales. Shipping and handling costs associated with inbound and outbound freight are expensed as incurred and included in freight and shipping expense.	(j) SHIPPING AND HANDLING FEES––Shipping and handling fees, if billed to customers, are included in product sales. Shipping and handling costs associated with inbound and outbound freight are expensed as incurred and included in freight and shipping expense.
Advertising Cost [Policy Text Block]	(k) ADVERTISING––Advertising costs are charged to operations when incurred. We incur minimal advertising expenses.	(k) ADVERTISING––Advertising costs are charged to operations when incurred. We incur minimal advertising expenses.
Research and Development Expense, Policy [Policy Text Block]	(l) RESEARCH AND DEVELOPMENT COSTS––Research and development costs are expensed as incurred.	(l) RESEARCH AND DEVELOPMENT COSTS––Research and development costs are expensed as incurred.
Income Tax, Policy [Policy Text Block]	(m) INCOME TAXES––Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In addition, tax benefits related to positions considered uncertain are recognized only when it is more likely than not 50%	(m) INCOME TAXES––Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In addition, tax benefits related to positions considered uncertain are recognized only when it is more likely than not 50% The Tax Cut and Jobs Act (the “Tax Act”) was enacted on December 22, 2017. 35% 21%. 80% January 1, 2018.
Earnings Per Share, Policy [Policy Text Block]	(n) NET LOSS PER COMMON SHARE––Basic and fully diluted net loss per common share is computed using a simple weighted average of common shares outstanding during the periods presented, as outstanding warrants to purchase 65,311,724 three six June 30, 2020 2019.	(n) NET LOSS PER COMMON SHARE––Basic and fully diluted net loss per common share is computed using a simple weighted average of common shares outstanding during the periods presented, as convertible preferred stock and outstanding warrants to purchase 63,321,294 32,192,294 2019 2018,
Share-based Payment Arrangement [Policy Text Block]	(o) STOCK BASED COMPENSATION–– The Company periodically awards stock to employees, directors, and consultants. In the case of employees and consultants, an expense is recognized equal to the fair value of the stock determined using the closing trading price of the stock on the award date. With respect to directors, the Company accrues stock compensation expense on a quarterly basis based on the Company's historical director compensation policies, and each quarter recognizes such expense based on the trading price of the common stock during such quarter.	(o) STOCK BASED COMPENSATION––The Company periodically awards stock to employees, directors, and consultants. An expense is recognized equal to the fair value of the stock determined using the closing trading price of the stock on the award date.
Fair Value Measurement, Policy [Policy Text Block]	(p) FAIR VALUE MEASUREMENTS AND DISCLOSURES––The Fair Value Measurements and Disclosures topic of the Accounting Standards Codification (“ASC”) requires companies to determine fair value based on the price that would be received to sell the asset or paid to transfer the liability to a market participant. The Fair Value Measurements and Disclosures topic emphasizes that fair value is a market-based measurement, not The guidance requires that assets and liabilities carried at fair value be classified and disclosed in one ● Level 1: ● Level 2: ● Level 3: not We have no June 30, 2020 December 31, 2019. For short-term classes of our financial instruments, which include cash, accounts receivable and accounts payable, and which are not June 30, 2020 December 31, 2019,	(p) FAIR VALUE MEASUREMENTS AND DISCLOSURES––The Fair Value Measurements and Disclosures topic of the Accounting Standards Codification (“ASC”) requires companies to determine fair value based on the price that would be received to sell the asset or paid to transfer the liability to a market participant. The Fair Value Measurements and Disclosures topic emphasizes that fair value is a market-based measurement, not The guidance requires that assets and liabilities carried at fair value be classified and disclosed in one ● Level 1: ● Level 2: ● Level 3: not We have no December 31, 2019 2018. For short-term classes of our financial instruments, which include cash, accounts receivable and accounts payable, and which are not December 31, 2019 2018,
Liquidity [Policy Text Block]	(q) LIQUIDITY AND GOING CONCERN––For the six June 30, 2020 December 31, 2019, $4,826,000 $7,533,000, $29,946,000 June 30, 2020. ® ® For the six June 30, 2020, $3,870,000 June 30, 2020, $1,008,000 $1,969,000. The Company has incurred losses from operations in each of the last six may Our consolidated financial statements for the three six June 30, 2020 December 31, 2019 five not	(q) LIQUIDITY AND GOING CONCERN––For the years ended December 31, 2019 2018, $7,533,000 $4,255,000, $25,120,000 December 31, 2019. ® ® For year ended December 31, 2019, $6,589,000 $7,120,000 December 31, 2019, $2,784,000 $817,000. The Company has incurred losses from operations in each of the last six may Our consolidated financial statements for the years ended December 31, 2019 2018 five not
Use of Estimates, Policy [Policy Text Block]	(r) USE OF ESTIMATES––The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions, including regarding contingencies, that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company's most significant estimate relates to inventory obsolescence. Although management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, actual results could significantly differ from these estimates.	(r) USE OF ESTIMATES––The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company's most significant estimate relates to inventory obsolescence. Although management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, actual results could significantly differ from these estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	(s) RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS–– In June 2016, 2016 13, 326 December 15, 2022, not In December 2019, 2019 12, Simplifying the Accounting for Income Taxes. 2019 12 2019 12 December 15, 2020. not	(s) RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS––In February 2016, 2016 02, 842 12 December 15, 2018, 842 January 1, 2019. 7. In December 2019, 2019 12, Simplifying the Accounting for Income Taxes. 2019 12 2019 12 December 15, 2020. not
Effect of Covid-19 Pandemic [Policy Text Block]	(t) UNCERTAINTY–– The recent outbreak of the COVID- 19 19 may may not 19 19 not 19, 19 9.

Note 2 - Revenues (Tables)

Note 2 - Revenues (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2020 2019 20 20 20 19 Trappsol ® $ - $ - $ 30,096 $ 25,971 Trappsol ® 151,188 135,878 366,150 206,746 Trappsol ® 55,631 39,100 133,740 104,952 Aquaplex ® 928 97,130 928 149,690 Other 1,847 987 4,414 6,562 Total revenues $ 209,594 $ 273,095 $ 535,328 $ 493,921	Year Ended December 31, 2019 2018 Trappsol ® $ 103,596 $ 166,596 Trappsol ® 481,379 484,101 Trappsol ® 265,947 233,910 Aquaplex ® 149,878 116,806 Other 6,398 10,064 Total revenues $ 1,007,198 $ 1,011,477

Note 9 - Note Payable (Tables)

Note 9 - Note Payable (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Maturities of Long-term Debt [Table Text Block]	Year Ending December 31, Amount 2020 $ 7,994 2021 $ 106,035 2022 $ 44,495 Total $ 158,524

Note 2 - Revenues 10K (Tables)

Note 2 - Revenues 10K (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2020 2019 20 20 20 19 Trappsol ® $ - $ - $ 30,096 $ 25,971 Trappsol ® 151,188 135,878 366,150 206,746 Trappsol ® 55,631 39,100 133,740 104,952 Aquaplex ® 928 97,130 928 149,690 Other 1,847 987 4,414 6,562 Total revenues $ 209,594 $ 273,095 $ 535,328 $ 493,921	Year Ended December 31, 2019 2018 Trappsol ® $ 103,596 $ 166,596 Trappsol ® 481,379 484,101 Trappsol ® 265,947 233,910 Aquaplex ® 149,878 116,806 Other 6,398 10,064 Total revenues $ 1,007,198 $ 1,011,477

Note 4 - Mortgage Note Receiv_3

Note 4 - Mortgage Note Receivable (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Participating Mortgage Loans [Table Text Block]	Year Ending December 31, Principal 2020 $ 39,061 2021 40,754 2022 42,520 2023 7,322 $ 129,657

Note 6 - Furniture and Equipm_2

Note 6 - Furniture and Equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	2019 2018 Machinery and equipment $ 16,524 $ 16,089 Office furniture 49,490 52,820 66,014 68,909 Less: accumulated depreciation 52,468 50,338 Furniture and equipment, net $ 13,546 $ 18,571

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year ending December 31, Amounts 2020 $ 19,170 2021 19,170 2022 19,170 2023 1,598 2024 - Total $ 59,108

Note 8 - Equity Transactions (T

Note 8 - Equity Transactions (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Share-based Compensation, Stock Warrants Activity [Table Text Block]	Warrants outstanding, December 31, 2017 20,632,331 Issued 11,559,963 Exercised - Expired - Warrants outstanding, December 31, 2018 32,192,294 Issued 31,129,000 Exercised - Expired - Warrants outstanding, December 31, 2019 63,321,294
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrants Issued Exercise Price Expiration Date 240,000 $ 0.25 April 2021 103,500 $ 1.00 July 2021 156,000 $ 0.50 July 2022 78,000 $ 0.50 August 2022 8,100,000 $ 0.25 June 2023 5,754,831 $ 0.35 February 2024 6,200,000 $ 0.25 October 2024 31,129,000 $ 0.30 November 2024 8,040,000 $ 0.25 April 2025 3,519,963 $ 0.65 December 2025 63,321,294

Note 10 - Income Taxes (Tables)

Note 10 - Income Taxes (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Notes Tables
Summary of Operating Loss Carryforwards [Table Text Block]		Year Ending December 31, Amount 2020 $ 174,000 2021 71,000 2024 66,000 2028 7,000 2030 160,000 2031 73,000 2032 48,000 2034 727,000 2035 1,969,000 2036 2,867,000 2037 2,481,000 Indefinite 9,692,000 Total $ 18,335,000
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2019 2018 Deferred tax assets: Net operating loss carryforwards $ 4,496,000 $ 3,017,000 Tax credits 4,292,000 3,085,000 Impairment allowances 13,000 10,000 Stock-based compensation 20,000 64,000 Other 62,000 62,000 Less valuation allowance (8,881,000 ) (6,235,000 ) Deferred tax asset, net of valuation 2,000 3,000 Deferred tax liabilities: Property and equipment (2,000 ) (3,000 ) Deferred tax liabilities (2,000 ) (3,000 ) Net tax assets $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]		2019 2018 Tax benefit (expense) at Federal statutory rate $ 1,582,000 $ 894,000 Effect of State taxes 265,000 185,000 Effect of tax rate change (102,000 ) - Tax credits 1,217,000 676,000 Nondeductible expenses (317,000 ) (180,000 ) Valuation allowance – deferred tax assets (2,645,000 ) (1,575,000 ) Total tax benefit (provision) $ - $ -

Note 1 - Summary of Significa_3

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended				6 Months Ended		9 Months Ended	12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Inventory Valuation Reserves, Ending Balance	$ 52,922				$ 52,922			$ 52,922	$ 39,700
Net Income (Loss) Attributable to Parent, Total	(2,192,392)	$ (2,633,992)	$ (1,368,011)	$ (1,904,166)	(4,826,384)	$ (3,272,177)		(7,532,533)	(4,255,033)
Retained Earnings (Accumulated Deficit), Ending Balance	(29,946,617)				(29,946,617)			(25,120,233)	(17,587,700)
Net Cash Provided by (Used in) Operating Activities, Total					(3,870,456)	$ (2,746,667)		(6,589,487)	(3,188,440)
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 1,008,355				1,008,355			2,783,719	$ 2,217,412	$ 1,270,973
Working Capital					$ 1,969,000			$ 817,000
Warrants To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	65,311,724		65,311,724		65,311,724	65,311,724
Computers and Vehicles [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)					3 years			3 years
Computers and Vehicles [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)					5 years			5 years
Machinery and Furniture [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)					7 years			7 years
Machinery and Furniture [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)					10 years		10 years

Note 2 - Revenues (Details Text

Note 2 - Revenues (Details Textual)	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Number of Operating Segments	1		1
Number of Major Customers	3	3	3
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Number of Major Customers	2	4	4	4
Aquaplex [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Number of Major Customers	3		3	1

Note 2 - Revenues - Revenues by

Note 2 - Revenues - Revenues by Product (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Revenues	$ 209,594	$ 273,095	$ 535,328	$ 493,921	$ 1,007,198	$ 1,011,477
Trappsol Cyclo [Member]
Revenues			30,096	25,971	103,596	166,596
Trappsol HPB [Member]
Revenues	151,188	135,878	366,150	206,746	481,379	484,101
Trappsol Fine Chemical [Member]
Revenues	55,631	39,100	133,740	104,952	265,947	233,910
Aquaplex [Member]
Revenues	928	97,130	928	149,690	149,878	116,806
Product and Service, Other [Member]
Revenues	$ 1,847	$ 987	$ 4,414	$ 6,562	$ 6,398	$ 10,064

Note 3 - Major Customers and _3

Note 3 - Major Customers and Suppliers (Details Textual)	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Number of Major Customers	3	3	3
Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Number of Major Customers	2	4	4	4
Concentration Risk, Percentage	60.00%	65.00%
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Biopharmaceuticals [Member]
Concentration Risk, Percentage	6.00%	6.00%
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Basic Natural and Chemically Modified Cyclodexterins [Member]
Concentration Risk, Percentage	94.00%	63.00%
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Cyclodexterin Complexes [Member]
Concentration Risk, Percentage		30.00%

Note 4 - Mortgage Note Receiv_4

Note 4 - Mortgage Note Receivable (Details Textual) - USD ($)	Jan. 21, 2016	Dec. 31, 2019
Proceeds from Sale of Property Held-for-sale	$ 10,000
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Face Amount of Mortgages	265,000	$ 129,657
Mortgage Loans on Real Estate, Monthly Payment	$ 3,653
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Interest Rate	4.25%

Note 5 - Equity Transactions (D

Note 5 - Equity Transactions (Details Textual)	Apr. 24, 2020USD ($)$ / sharesshares	May 31, 2019USD ($)$ / sharesshares	May 30, 2019USD ($)$ / sharesshares	Jan. 30, 2019USD ($)	Apr. 30, 2018USD ($)$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2019USD ($)	Mar. 30, 2018USD ($)	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)$ / sharesshares
Share-based Payment Arrangement, Expense | $						$ 6,840	$ 36,540		$ 14,060	$ 67,930	$ 168,120	$ 83,420
Equity Units, Number of Common Shares in Each Unit (in shares)												1
Proceeds from Issuance of Private Placement | $								$ 74,983
Proceeds from Issuance or Sale of Equity, Net of Issuance Costs | $											$ 7,120,000
Warrants Issued with Units [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.30			$ 0.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					400
Warrants Issued to Placement Agent in Connection with Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		1,359,000
Warrants Issued to Placement Agent in Connection with Private Placement [Member] | Think Equity [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 0.11
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			222,282
Class of Warrant or Right, Issued During Period, Percentage of Purchased Common Stock			6.00%
Class of Warrant or Right, Exercise Price, Percentage Price Per Share Paid by Investors			110.00%
Warrants To Purchase Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						63,543,576			63,543,576
Warrants To Purchase Common Stock [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 0.11			$ 0.11
Warrants To Purchase Common Stock [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						1			1
Warrants to Purchase Units Sold in May 2016 Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 0.25			$ 0.25			$ 0.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						480,000			480,000			480,000
Warrants and Rights Outstanding, Term (Year)						7 years			7 years
Warrants to Purchase Units Sold in February 2017 Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 0.35			$ 0.35			$ 0.35
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						164,074			164,074			164,074
Warrants to Purchase Units Sold in October 2017 Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 100			$ 100			$ 100
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						600			600			600
Private Placement [Member]
Equity Units Issued During Period, Shares, New Issues (in shares)		29,770,000			20,100							3,519,963
Shares Issued, Price Per Share (in dollars per share) | $ / shares	$ 0.10	$ 0.25
Equity Units, Number of Common Shares in Each Unit (in shares)		1
Equity Units, Number of Warrants in Each Unit		1
Proceeds from Issuance of Private Placement | $	$ 2,000,000	$ 7,442,500		$ 130,063	$ 2,010,000							$ 2,342,034
Payments of Stock Issuance Costs | $		452,900
Proceeds from Issuance or Sale of Equity, Net of Issuance Costs | $		$ 6,989,600
Stock Issued During Period, Shares, New Issues (in shares)	20,000,000
May Placement [Member] | Think Equity [Member]
Payments of Stock Issuance Costs | $			$ 29,637
Stock or Equity Unit Issuance, Cash Fee, Percentage of Gross Proceeds			8.00%

Note 7 - Equity Incentive Plan

Note 7 - Equity Incentive Plan (Details Textual) - The 2019 Omnibus Incentive Plan [Member] - shares	4 Months Ended	10 Months Ended
	Dec. 31, 2019	Jun. 30, 2020	Aug. 29, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)			6,843,750
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	450,000	450,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	6,393,750	6,393,750
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years	10 years

Note 8 - Leases (Details Textua

Note 8 - Leases (Details Textual)	6 Months Ended		12 Months Ended
	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Operating Lease, Right-of-Use Asset, Amortization	$ 25,507		$ 17,006
Operating Lease, Expense	$ 8,929	$ 11,376	$ 17,006	$ 22,249
Office Lease [Member]
Number of Operating Leases	1		1

Note 9 - Note Payable (Details

Note 9 - Note Payable (Details Textual) - USD ($)	May 04, 2020	Jun. 30, 2020	Jun. 30, 2019
Proceeds from Issuance of Long-term Debt, Total		$ 158,524
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Long-term Debt, Total	$ 158,524

Note 9 - Note Payable - Maturit

Note 9 - Note Payable - Maturities of Note Payable (Details) - Paycheck Protection Program CARES Act [Member]	Jun. 30, 2020USD ($)
2020	$ 7,994
2021	106,035
2022	44,495
Total	$ 158,524

Note 1 - Summary of Significa_4

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended				6 Months Ended		9 Months Ended	12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Inventory Valuation Reserves, Ending Balance	$ 52,922				$ 52,922			$ 52,922	$ 39,700
Net Income (Loss) Attributable to Parent, Total	(2,192,392)	$ (2,633,992)	$ (1,368,011)	$ (1,904,166)	(4,826,384)	$ (3,272,177)		(7,532,533)	(4,255,033)
Retained Earnings (Accumulated Deficit), Ending Balance	(29,946,617)				(29,946,617)			(25,120,233)	(17,587,700)
Net Cash Provided by (Used in) Operating Activities, Total					(3,870,456)	$ (2,746,667)		(6,589,487)	(3,188,440)
Proceeds from Issuance or Sale of Equity, Net of Issuance Costs								7,120,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 1,008,355				1,008,355			2,783,719	$ 2,217,412	$ 1,270,973
Working Capital					$ 1,969,000			$ 817,000
Fair Value, Recurring [Member]
Financial and Nonfinancial Liabilities, Fair Value Disclosure							$ 0
Warrants To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)								63,321,294	32,192,294
Computers and Vehicles [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)					3 years			3 years
Computers and Vehicles [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)					5 years			5 years
Machinery and Furniture [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)					7 years			7 years
Machinery and Furniture [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)					10 years		10 years

Note 2 - Revenues 10K (Details

Note 2 - Revenues 10K (Details Textual)	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Number of Operating Segments	1		1
Number of Major Customers	3	3	3
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Number of Major Customers	2	4	4	4
Aquaplex [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Number of Major Customers	3		3	1

Note 2 - Revenues - Revenues _2

Note 2 - Revenues - Revenues by Product 10K (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Revenues	$ 209,594	$ 273,095	$ 535,328	$ 493,921	$ 1,007,198	$ 1,011,477
Trappsol Cyclo [Member]
Revenues			30,096	25,971	103,596	166,596
Trappsol HPB [Member]
Revenues	151,188	135,878	366,150	206,746	481,379	484,101
Trappsol Fine Chemical [Member]
Revenues	55,631	39,100	133,740	104,952	265,947	233,910
Aquaplex [Member]
Revenues	928	97,130	928	149,690	149,878	116,806
Product and Service, Other [Member]
Revenues	$ 1,847	$ 987	$ 4,414	$ 6,562	$ 6,398	$ 10,064

Note 3 - Major Customers and _4

Note 3 - Major Customers and Suppliers (Details Textual)	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Number of Major Customers	3	3	3
Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Number of Major Customers	2	4	4	4
Concentration Risk, Percentage	60.00%	65.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Four Major Customer [Member]
Concentration Risk, Percentage			70.00%	57.00%
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Biopharmaceuticals [Member]
Concentration Risk, Percentage	6.00%	6.00%
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Basic Natural and Chemically Modified Cyclodexterins [Member]
Concentration Risk, Percentage	94.00%	63.00%
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Cyclodexterin Complexes [Member]
Concentration Risk, Percentage		30.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Four Major Customer [Member]
Concentration Risk, Percentage			95.00%	31.00%
Revenue, Product and Service Benchmark [Member] | Product Concentration Risk [Member] | Biopharmaceuticals [Member]
Concentration Risk, Percentage			10.00%	17.00%
Revenue, Product and Service Benchmark [Member] | Product Concentration Risk [Member] | Basic Natural and Chemically Modified Cyclodexterins [Member]
Concentration Risk, Percentage			75.00%	71.00%
Revenue, Product and Service Benchmark [Member] | Product Concentration Risk [Member] | Cyclodexterin Complexes [Member]
Concentration Risk, Percentage			15.00%	12.00%

Note 4 - Mortgage Note Receiv_5

Note 4 - Mortgage Note Receivable (Details Textual) - USD ($)	Jan. 21, 2016	Dec. 31, 2019
Proceeds from Sale of Property Held-for-sale	$ 10,000
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Face Amount of Mortgages	265,000	$ 129,657
Mortgage Loans on Real Estate, Monthly Payment	$ 3,653
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Interest Rate	4.25%

Note 4 - Mortgage Note Receiv_6

Note 4 - Mortgage Note Receivable - Scheduled Debt Principal Collections on Mortgage Note Receivable (Details) - USD ($)	Dec. 31, 2019	Jan. 21, 2016
2020	$ 39,061
2021	40,754
2022	42,520
2023	7,322
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Face Amount of Mortgages	$ 129,657	$ 265,000

Note 6 - Furniture and Equipm_3

Note 6 - Furniture and Equipment - Summary of Property and Equipment (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Property, plant and equipment, gross		$ 66,014	$ 68,909
Less: accumulated depreciation		52,468	50,338
Furniture and equipment, net	$ 60,437	13,546	18,571
Machinery and Equipment [Member]
Property, plant and equipment, gross		16,524	16,089
Office Furniture [Member]
Property, plant and equipment, gross		$ 49,490	$ 52,820

Note 7 - Leases (Details Textua

Note 7 - Leases (Details Textual)	6 Months Ended		12 Months Ended
	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Operating Lease, Right-of-Use Asset, Amortization	$ 25,507		$ 17,006
Operating Lease, Expense	$ 8,929	$ 11,376	$ 17,006	$ 22,249
Office Lease [Member]
Number of Operating Leases	1		1

Note 7 - Leases - Operating Lea

Note 7 - Leases - Operating Lease Maturity (Details)	Dec. 31, 2019USD ($)
2020	$ 19,170
2021	19,170
2022	19,170
2023	1,598
2024
Total	$ 59,108

Note 8 - Equity Transactions (D

Note 8 - Equity Transactions (Details Textual)	Apr. 24, 2020USD ($)$ / shares	May 31, 2019USD ($)$ / sharesshares	May 23, 2018shares	Jan. 30, 2019USD ($)	Apr. 30, 2018USD ($)$ / sharesshares	Apr. 30, 2014	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2019USD ($)	Mar. 30, 2018USD ($)	Apr. 30, 2018$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017shares	May 22, 2018shares	Oct. 31, 2017shares
Share-based Payment Arrangement, Expense | $							$ 6,840	$ 36,540			$ 14,060	$ 67,930	$ 168,120	$ 83,420
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture (in shares)														0
Proceeds from Issuance of Private Placement | $									$ 74,983
Common Stock, Shares Authorized (in shares)			500,000,000				500,000,000				500,000,000		500,000,000	500,000,000		100,000,000
Conversion of Preferred Stock to Common Stock, Number of Shares Issued Per Share Converted (in shares)			400
Increase (Decrease) in Number of Common Shares Outstanding (in shares)			14,240,000
Equity Units, Number of Common Shares in Each Unit (in shares)														1
Proceeds from Issuance or Sale of Equity, Net of Issuance Costs | $													$ 7,120,000
Series B Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)																	400
Scarsdale Agreement Warrants [Member]
Term of Warrant (Year)										7 years
Class of Warrant or Right, Percentage of Securities Issued Called by Warrants or Rights						6.00%
Class of Warrant or Right, Exercise Price, Percentage of Offering Price						100.00%
Warrants Issued with Units [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					400					400
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.30			$ 0.25					$ 0.25
Warrants To Purchase Common Stock [Member]
Term of Warrant (Year)														7 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							63,543,576				63,543,576
Warrants Issued to Placement Agent in Connection with Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		1,359,000
Warrants to Purchase Units Sold in May 2016 Private Placement [Member]
Term of Warrant (Year)														7 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							480,000				480,000			480,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares							$ 0.25				$ 0.25			$ 0.25
Warrants to Purchase Units Sold in February 2017 Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							164,074				164,074			164,074
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares							$ 0.35				$ 0.35			$ 0.35
Warrants to Purchase Units Sold in October 2017 Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							600				600			600
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares							$ 100				$ 100			$ 100
Financial Advisory and Exclusive Placement Agent Agreement [Member] | Scarsdale [Member]
Private Placement Fee, Percentage of Proceeds						6.00%
Private Placement [Member]
Equity Units, Number of Series B Convertible Preferred Stock in Each Unit (in shares)					1					1
Term of Warrant (Year)										7 years
Equity Units Issued During Period, Shares, New Issues (in shares)		29,770,000			20,100									3,519,963
Share Price (in dollars per share) | $ / shares					$ 100					$ 100				$ 0.65
Proceeds from Issuance of Private Placement | $	$ 2,000,000	$ 7,442,500		$ 130,063	$ 2,010,000									$ 2,342,034
Payment for Cash Fee | $														$ 50,000
Equity Units, Number of Common Shares in Each Unit (in shares)		1
Shares Issued, Price Per Share (in dollars per share) | $ / shares	$ 0.10	$ 0.25
Equity Units, Number of Warrants in Each Unit		1
Payments of Stock Issuance Costs | $		$ 452,900
Proceeds from Issuance or Sale of Equity, Net of Issuance Costs | $		$ 6,989,600
Private Placement [Member] | Series B Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)					400					400
Employees [Member]
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture (in shares)													450,000
Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture | $													$ 87,750
Director [Member]
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture (in shares)													241,666
Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture | $													$ 109,908
Board Members and Officers [Member]
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture (in shares)													344,000
Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture | $													$ 158,670
Share Based Payment Arrangement By Share Based Compensation Arrangement, Deferred Compensation, Shares Acrrued (in shares)														172,000	172,000

Note 8 - Equity Transactions -

Note 8 - Equity Transactions - Common Stock Warrants Outstanding (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Warrants outstanding (in shares)	32,192,294	20,632,331
Issued (in shares)	31,129,000	11,559,963
Exercised (in shares)
Expired (in shares)
Warrants outstanding (in shares)	63,321,294	32,192,294

Note 8 - Equity Transactions _2

Note 8 - Equity Transactions - Summary of Warrants Outstanding, Exercise Price, and Expiration Dates (Details) - $ / shares	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Warrants Issued (in shares)	63,321,294	32,192,294	20,632,331
Warrants Issued (in shares)	63,321,294	32,192,294	20,632,331
Warrants Expiring in April 2021 [Member]
Warrants Issued (in shares)	240,000
Exercise Price (in dollars per share)	$ 0.25
Warrants Issued (in shares)	240,000
Warrants Expiring in July 2021 [Member]
Warrants Issued (in shares)	103,500
Exercise Price (in dollars per share)	$ 1
Warrants Issued (in shares)	103,500
Warrants Expiring in July 2022 [Member]
Warrants Issued (in shares)	156,000
Exercise Price (in dollars per share)	$ 0.50
Warrants Issued (in shares)	156,000
Warrants Expiring in August 2022 [Member]
Warrants Issued (in shares)	78,000
Exercise Price (in dollars per share)	$ 0.50
Warrants Issued (in shares)	78,000
Warrants Expiring in June 2023 [Member]
Warrants Issued (in shares)	8,100,000
Exercise Price (in dollars per share)	$ 0.25
Warrants Issued (in shares)	8,100,000
Warrants Expiring in February 2024 [Member]
Warrants Issued (in shares)	5,754,831
Exercise Price (in dollars per share)	$ 0.35
Warrants Issued (in shares)	5,754,831
Warrants Expiring in October 2024 [Member]
Warrants Issued (in shares)	6,200,000
Exercise Price (in dollars per share)	$ 0.25
Warrants Issued (in shares)	6,200,000
Warrants Expiring in November 2024 [Member]
Warrants Issued (in shares)	31,129,000
Exercise Price (in dollars per share)	$ 0.30
Warrants Issued (in shares)	31,129,000
Warrants Expiring in April 23, 2025 [Member]
Warrants Issued (in shares)	8,040,000
Exercise Price (in dollars per share)	$ 0.25
Warrants Issued (in shares)	8,040,000
Warrants Expiring in December, 2025 [Member]
Warrants Issued (in shares)	3,519,963
Exercise Price (in dollars per share)	$ 0.65
Warrants Issued (in shares)	3,519,963

Note 9 - Preferred Stock (Detai

Note 9 - Preferred Stock (Details Textual) - $ / shares	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018	Oct. 31, 2017	Oct. 17, 2017	Dec. 31, 2004
Preferred Stock, Shares Authorized (in shares)	5,000,000	5,000,000	5,000,000			5,000,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)		0	0
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)					50,000
Preferred Stock, Shares Issued, Total (in shares)					35,600
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)				400
Preferred Stock, Liquidation Preference Per Share (in dollars per share)				$ 100

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Deferred Tax Asset Based Upon Expected Income Tax Rates					$ 8,881,000
Valuation Allowance Percentage					100.00%
Operating Loss Carryforwards, Total					$ 18,335,000
Income Tax Expense (Benefit), Total					0	$ 0
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount					2,645,000	1,575,000
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Ending Balance						$ 768,000
State and Local Jurisdiction [Member] | Florida Department of Revenue [Member]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount					$ (102,000)
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent					4.458%	5.50%
Orphan Drug Credit [Member]
Tax Credit Carryforward, Amount					$ 4,292,000

Note 10 - Income Taxes - Summar

Note 10 - Income Taxes - Summary of Net Operating Loss Carryforward Expirations (Details)	Dec. 31, 2019USD ($)
Net operating loss carryforwards	$ 18,335,000
Expiring in Tax Year 2020 [Member]
Net operating loss carryforwards	174,000
Expiring in Tax Year 2021 [Member]
Net operating loss carryforwards	71,000
Expiring in Tax Year 2024 [Member]
Net operating loss carryforwards	66,000
Expiring in Tax Year 2028 [Member]
Net operating loss carryforwards	7,000
Expiring in Tax Year 2030 [Member]
Net operating loss carryforwards	160,000
Expiring in Tax Year 2031 [Member]
Net operating loss carryforwards	73,000
Expiring in Tax Year 2032 [Member]
Net operating loss carryforwards	48,000
Expiring in Tax Year 2034 [Member]
Net operating loss carryforwards	727,000
Expiring in Tax Year 2035 [Member]
Net operating loss carryforwards	1,969,000
Expiring in Tax Year 2036 [Member]
Net operating loss carryforwards	2,867,000
Expiring in Tax Year 2037 [Member]
Net operating loss carryforwards	2,481,000
Expiring in Tax Year indefinite [Member]
Net operating loss carryforwards	$ 9,692,000

Note 10 - Income Taxes - Summ_2

Note 10 - Income Taxes - Summary of Significant Components of Deferred Federal Income Taxes (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets:
Net operating loss carryforwards	$ 4,496,000	$ 3,017,000
Tax credits	4,292,000	3,085,000
Impairment allowances	13,000	10,000
Stock-based compensation	20,000	64,000
Other	62,000	62,000
Less valuation allowance	(8,881,000)	(6,235,000)
Deferred tax asset, net of valuation	2,000	3,000
Deferred tax liabilities:
Property and equipment	(2,000)	(3,000)
Deferred tax liabilities	(2,000)	(3,000)
Net tax assets

Note 10 - Income Taxes - Summ_3

Note 10 - Income Taxes - Summary of Differences Between the Effective Income Tax Rate Reflected in Benefit (Provision) for Income Taxes Amount (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Tax benefit (expense) at Federal statutory rate					$ 1,582,000	$ 894,000
Effect of State taxes					265,000	185,000
Effect of tax rate change					(102,000)
Tax credits					1,217,000	676,000
Nondeductible expenses					(317,000)	(180,000)
Valuation allowance – deferred tax assets					(2,645,000)	(1,575,000)
Total tax benefit (provision)					$ 0	$ 0

Note 11 - Employee Benefit Pl_2

Note 11 - Employee Benefit Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay		4.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 29,410	$ 24,765

Note 12 - Equity Incentive Pl_2

Note 12 - Equity Incentive Plan (Details Textual) - The 2019 Omnibus Incentive Plan [Member] - shares	4 Months Ended	10 Months Ended
	Dec. 31, 2019	Jun. 30, 2020	Aug. 29, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)			6,843,750
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	450,000	450,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	6,393,750	6,393,750
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years	10 years

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingencies (Details Textual) - Office and Distribution Warehouse Space [Member]	Nov. 26, 2018USD ($)ft²
Lessee, Operating Lease, Term of Contract (Year)	2 years
Area of Leasing Property (Square Foot) | ft²	2,500
Operating Lease, Monthly Payment | $	$ 1,600
Lessee, Operating Lease, Renewal Term (Year)	2 years

Note 14 - Related Party Trans_2

Note 14 - Related Party Transactions (Details Textual) - USD ($)	1 Months Ended				2 Months Ended	12 Months Ended		27 Months Ended
	Jun. 30, 2019	Jan. 31, 2019	Oct. 30, 2018	Jan. 31, 2018	Dec. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2018	Jun. 30, 2020	Sep. 30, 2019
Common Stock, Shares, Issued, Total (in shares)						121,564,990	90,759,324	90,759,324	141,671,462
C.E. Rick Strattan [Member]
Payments for Non-profit Organization, Monthly Fee								$ 5,000
Joshua M. Fine [Member]
Annual Salary for Chief Financial Officer	$ 125,000
Common Stock, Shares, Issued, Total (in shares)										50,000
Rebecca A. Fine [Member]
Common Stock, Shares, Issued, Total (in shares)										25,000
Independent Contractor, Service, Monthly Rate							$ 5,000
Independent Contractor, Monthly Rate							5,800
Annual Salary for Executive Assistant	$ 69,600
Kevin J. Strattan [Member]
Common Stock, Shares, Issued, Total (in shares)										50,000
Annual Salary for Vice President, Finance			$ 107,200		$ 100,000
Bonus for Vice President, Finance						$ 12,500	10,000
Corey E. Strattan [Member]
Common Stock, Shares, Issued, Total (in shares)										25,000
Annual Salary for Documentation Specialist and Logistics Coordinator		$ 78,000		$ 72,000
Bonus for Documentation Specialist and Logistics Coordinator							$ 5,000